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Identification of Small Molecule Inhibitors of 3-Phosphoglycerate 
Dehydrogenase to Target Serine Biosynthesis in Cancers 
 
Abstract 
 
Cancer cells are known to reprogram their metabolism in order to promote 
growth and proliferation. The amino acid serine is utilized in a plethora of 
anabolic reactions and supports the synthesis of all three major macromolecular 
classes: proteins, lipids, and nucleic acids. Serine can either be synthesized de 
novo via the phosphoserine pathway or imported from the extracellular space via 
amino acid transporters. The gene encoding the enzyme 3-phosphoglycerate 
dehydrogenase (PHGDH), which catalyzes the first committed step of the 
phosphoserine pathway, is focally amplified in human cancers suggesting that it 
is pro-tumorigenic. Cancer cell lines that harbor PHGDH amplifications, or over 
express PHGDH independently of amplification, are uniquely sensitive to genetic 
ablation of the pathway. In contrast, cancer cell lines that express little PHGDH, 
and instead rely on serine import, are resistant to genetic ablation of the 
pathway. Given these observations, we speculated that PHGDH might be a 
clinically interesting target in oncology and sought to develop small molecule 
inhibitors of PHGDH in order to provide tool compounds with which to study the 
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biology of PHGDH and evaluate the efficacy of inhibiting serine synthesis in 
cancers.  
 In order to identify inhibitors of PHGDH an in vitro enzymatic assay was 
developed and libraries of drug-like small molecules were screened. Hit 
compounds were validated in biochemical assays to determine potency and 
selectivity for PHGDH. Selected compounds were tested on cells for their ability 
to inhibit de novo serine synthesis and one lead, CBR-5884, was identified.   
CBR-5884 was selectively toxic to PHGDH amplified or overexpressing cancer 
cells but had no effect on cells that express little PHGDH. Mechanistically, CBR-
5884 was found to be a non-competitive inhibitor that showed a time dependent 
onset of inhibition and disrupted the oligomerization state of PHGDH. These 
results provide a proof-of-concept for targeting PHGDH and suggest that 
inhibiting PHGDH in cancers addicted to serine synthesis is a potentially viable 
targeted therapy option.  
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Chapter 1: Introduction 
 
A Brief Overview of Cancer Cell Metabolism 
 
Since Warburg’s pioneering work, cancer cells have been known to 
reprogram their metabolism in order to promote growth and proliferation 1. 
Indeed, metabolic alterations have now been accepted as a hallmark of cancer 
and many oncogenes including PI3K, Akt, and KRAS reprogram cellular 
metabolism 2,3,4,5,6. Although it is now known that defective mitochondria are 
generally not the cause of aerobic glycolysis, the benefits of enhanced glycolysis 
remain an active area of research. In part, enhanced glycolysis allows glycolytic 
intermediates to be funneled into anabolic pathways 7. In order to divide, a cell 
needs to duplicate its protein, lipid, and nucleic acid content. Nucleotides, amino 
acids, lipids, and cellular reducing power in the form of NADPH – critical for 
reductive biosynthesis and maintaining redox homeostasis – can all be produced 
by shunting flux away from glycolysis 8. In addition, cancer cells are avid 
consumers of glutamine, the most abundant amino acid in plasma 2,9. As is the 
case for glucose, glutamine consumption seems to drive anabolic metabolism 
and is activated by oncogenes such as cMyc 2,10,11. Glutamine is a nitrogen donor 
for nucleotide and hexosamine synthesis. Via glutaminolysis, glutamine is a 
major contributor to anaplerotic flux for the TCA cycle and provides nonessential 
amino acids 9. In addition, it is now apparent that despite enhanced glycolysis, 
many cancer cells still rely on oxidative phosphorylation for ATP production 7,12,13. 
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Thus, one of the fundamental adaptations of a cancerous cell is to rewire 
metabolism to promote biosynthesis. Much of the work on cancer metabolism 
stems from the belief that the idiosyncrasies of tumor metabolism will provide an 
Achilles’ heel for the development of new targeted therapies 9,14,15. 
 
Cellular Synthesis and Catabolism of Serine 
 
 Serine is a non-essential amino acid in that it can be synthesized de novo 
from glucose or from glycine, and dietary intake is therefore unnecessary. 
However, as noted by Eagle in the late 1950s, serine is better characterized as a 
conditionally essential amino acid, akin to glutamine, in that de novo serine 
synthesis can be insufficient to sustain cell proliferation in culture when serine is 
omitted from the media 16. Serine synthesis from glucose proceeds via the 
phosphoserine pathway in three sequential enzymatic reactions. The first 
committed step is catalyzed by the enzyme 3-phosphoglycerate dehydrogenase 
(PHGDH), which oxidizes the glycolytic intermediate 3-phosphoglycerate (3-PG) 
to 3-phosphohydroxy pyruvate (pPYR) in an NAD+ dependent mechanism. 
Subsequently, phosphoserine aminotransferase (PSAT1) transaminates pPYR to 
yield phosphoserine (pSER) using glutamate as the nitrogen donor. Finally, 
phosphoserine phosphatase (PSPH) hydrolyzes the pSER phosphate to yield 
serine (Figure 1.1) 17. The equilibria of PHGDH and PSAT1 lie towards 3-PG and 
pPYR, respectively, thus ensuring that when PSPH is feedback inhibited by its 
product serine, the pathway as a whole is effectively inhibited 18,19. Serine can be 
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synthesized from glycine via serine hydroxymethyltransferases (SHMTs) 
consuming 5,10-methylenetetrahydrofolate (CH2-THF). Generally, the cytosolic 
isozyme, SHMT1, favors serine synthesis while the mitochondrial isozyme, 
SHMT2, catabolizes serine to produce glycine and CH2-THF 20. In addition to de 
novo synthesis, serine can be imported from the extracellular space via amino 
acid transporters such as the commonly expressed ASC system members, 
ASCT1 (SLC1A4) and ASCT2 (SLC1A5), which mediate the symport of alanine, 
serine or cysteine with sodium 21. 
 
 
 
Figure 1.1 The Phosphoserine Pathway. The phosphoserine pathway enables 
serine synthesis from the glycolytic intermediate 3-phosphoglyerate. 
Phosphoglycerate dehydrogenase (PHGDH) oxidizes the glycolytic intermediate 
3-phosphoglycerate (3-PG) to 3-phosphohydroxypyruvate (pPYR) using NAD+; 
phosphoserine amino transferase (PSAT1) transaminates pPYR to 
phosphoserine (pSER) using glutamate as a nitrogen donor; phosphoserine 
phosphatase (PSPH) dephosphorylates pSER to yield serine. Serine can be 
converted to glycine (GLY) via the action of serine hydroxymethyltransferases 
(SHMTs). 
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 In addition to the SHMT2 reaction, serine can be catabolized via the non-
phosphorylated serine pathway or via serine dehydratase. Initially, it was thought 
that there were two pathways for serine synthesis from glucose – one based on 
phosphorylated intermediates and the other on unphosphorylated intermediates  
(Figure 1.2) 18. The apparent dilemma was resolved when it was understood that 
the non-phosphorylated pathway was one of catabolism 22. Akin to the 
phosphoserine pathway, the non-phosphorylated pathway proceeds in three 
steps. Initially, serine-pyruvate transaminase (SPT) transfers the serine amino 
group to pyruvate to yield alanine and hydroxypyruvate. Hydroxypyruvate is then 
reduced by glycerate dehydrogenase (GDH) to glycerate, which is then 
phosphorylated by glycerate kinase (GK) to give the glycolytic metabolite 2-
phosphoglycerate (Figure 1.2) 18. Thus, the phosphorylated and non-
phosphorylated pathways are antiparallel; the former drawing flux away from 
glycolysis to produce serine, the latter returning serine derived carbon to 
glycolysis. Interestingly, SPT also has transaminase activity for glyoxylate and 
alanine, producing glycine and pyruvate. Germline loss-of-function mutations in 
SPT lead to hyperoxalurias due to the excessive production of oxalate from 
glyoxylate 23. Serine catabolism via serine dehydratase (SDH) proceeds in a 
single step to yield pyruvate and ammonia (Figure 1.2). While the phosphoserine 
pathway enzymes and the SHMTs are widely disrupted across tissues, both the 
non-phosphorylated and SDH reactions occur predominantly in the 
gluconeogenic tissues of the kidneys and liver 18,23.  
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Figure 1.2. Serine synthesis and catabolism. Serine synthesis from glucose 
via the phosphoserine pathway (green arrows). Serine catabolism shown with 
red arrows can proceed either through (i) the non-phosphorylated pathway or (ii) 
serine dehydratase (SDH). The non-phosphorylated pathway consists of three 
sequential reactions: serine pyruvate transaminase (SPT), glycerate 
dehydrogenase (GDH), glycerate kinase (GK).  
 
 
 
Anabolic Roles of Serine in Cellular Metabolism 
 
Serine is an abundant component of proteins and is required for the 
synthesis of lipid head groups including sphingolipids and phosphatidylserine, a 
major component of cellular membranes (Figure 1.3) 24-26. Indeed, serine 
deficiency in PHGDH knockout MEFs has been shown to cause abnormal 
sphingolipid profiles and the accumulation of potentially toxic deoxysphingolipids 
resulting from the incorporation of alanine instead of serine into lipid head groups 
27. Whereas other metabolites such as betaine (trimethylglycine) can donate one-
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carbon units to the folate pool, serine is the major provider of one-carbon units to 
the folate cycle 28. The hydroxymethyl group of the serine side chain enters the 
folate pool via the tetrahydrofolate (THF) dependent action of serine 
hydroxymethyltransferases (SHMT) yielding glycine and 
methylenetetrahydrofolate (CH2-THF) (Figure 1.3). Importantly, the production of 
glycine and folate one-carbon units enables serine to contribute to nucleotide 
production. Glycine’s nitrogen and two carbon atoms are incorporated directly 
into purine rings (Figure 1.3). In addition, serine derived folate one carbon units 
are incorporated into the purine ring and used to methylate dUMP to produce 
dTMP. Mechanistically, mitochondrial SHMT2 catabolizes serine to generate 
CH2-THF. The methylene moiety of CH2-THF is then sequentially oxidized to 
methenyl-THF, formyl-THF, and free formate by the mitochondrial folate pathway 
enzymes (MTHFD2 or MTHFD2L and MTHFD1L)20. Eventually, the formate 
effluxes from the mitochondria to the cytosol where it is a substrate for formate-
THF synthetase and is thus reincorporated into the folate pool as formyl-THF. It 
is the serine derived cytosolic formyl-THF that is directly consumed to make 
purines; formyl-THF units are incorporated into a purine ring at positions 2 and 8 
28,29. Thymidylate synthase (TS) consumes CH2-THF directly to generate dTMP. 
The above discussion illustrates how serine contributes to the synthesis of all 
three major macromolecular classes, proteins, lipids, and nucleic acids, and is 
thus critical for biomass accumulation.  
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Figure 1.3. Anabolic roles of serine. Serine is either imported from the 
extracellular space or synthesized de novo. Serine is required for protein 
synthesis and is incorporated into the head groups of certain lipids, including 
phosphatidylserine and sphingosine. Importantly, serine can be converted to 
glycine by the action of SHMTs concomitantly charging the folate pool with a 
one-carbon unit in the form of CH2-THF. Glycine and one-carbon units are 
required for nucleotide synthesis. Folate one carbon units can regenerate SAM 
from homocysteine. SAM is the major methyl donor for methyl transferase 
reactions and is used to produce polyamines. Via the transsulfuration pathway, 
serine can generate cysteine; both cysteine and glycine are required for 
glutathione synthesis.  
 
 
Beyond supporting biomass production, serine is used to generate a 
plethora of small-molecule metabolites critical for cellular homeostasis and 
molecular biology processes. The methionine cycle enables the synthesis of S-
adenosylmethionine (SAM), which functions as the universal methyl donor for 
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cellular methylation reactions including those of DNA, mRNA caps, histones, and 
other proteins 30,31. While SAM can be synthesized de novo from the conjugation 
of methionine and the adenosine moiety of ATP via SAM synthetase, the salvage 
pathway relies on methylation of homocysteine to regenerate methionine. 
Importantly, the vitamin B12 dependent enzyme homocysteine methyltransferase 
consumes cytosolic methyl-THF to regenerate methionine and liberate THF 30,31. 
Thus, serine derived folate one carbon units serve to regenerate SAM for cellular 
methylation reactions. In addition, SAM can be used for polyamine synthesis. 
Serine derived formyl-THF is also needed to produce formyl-methionine, which is 
used as the initiation codon in mitochondrial protein synthesis 32. Serine can also 
be use to produce cysteine via the transsulfuration pathway; serine combines 
with homocysteine to yield cystathionine that is then hydrolyzed to cysteine and 
homoserine by cystathionase. Glutathione (GSH), which protects cells against 
oxidative and xenobiotic stress, is an enzymatically-synthesized tripeptide of 
glutamate, cysteine and glycine. Thus, up to two moles of serine can be 
consumed per mole of GSH produced 33. Finally, mitochondrial glycine derived 
from serine can contribute to heme biosynthesis. Aminolevulinic acid synthase 
(ALAS), the first enzyme of the heme biosynthesis pathway, catalyzes the 
condensation reaction of glycine and succinyl-CoA to yield 5-aminolevulinic acid 
(ALA) 34.  
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Serine Synthesis in Cancer, a Historical Perspective 
 
 Historically, the importance of serine synthesis in cancer was studied by 
investigating the activities of serine synthesis and catabolism enzymes in 
homogenates of neoplastic tissues and by tracing the incorporation of radioactive 
serine, glycine, or glucose into nucleotides 35. The studies revealed that in 
various tumor types ranging from rat sarcomas to human colon carcinomas, 
phosphoserine pathway activity and SHMT activity were increased compared to 
normal control tissues. In contrast, the activities of serine catabolism enzymes, 
SDH and SPT, were suppressed 35-37. Importantly, it was noted that in 
proliferating hepatoma cells PHGDH and SHMT activity followed the same 
temporal regulation. Moreover, activity mirrored the incorporation of 14C-serine or 
14C-gluocse into nucleotide bases 38,39. Similar results were obtained with the 
study of lymphocytes following mitogenic stimulation, indicating that this 
particular metabolic flow is common among proliferating cells 39. Combined, 
these observations led Snell to propose a general model in which the enhanced 
capacity for serine synthesis in cancer cells is utilized to generate glycine and 
one-carbon units for purine and thymidine synthesis 40. Much of the recent work 
in the field of serine cancer metabolism corroborates Snell’s hypothesis 41,42 43. 
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Serine Synthesis in Cancer, a Modern Perspective 
 
 The renewed interest in the role of serine synthesis in cancer emerged 
following the publication of two studies that sought to identify metabolic pathways 
important for tumorigenesis. Despite different functional screening 
methodologies, both studies converged on PHGDH 44,45. The first study traced 
the metabolism of uniformly carbon-13 labeled glucose (U-13C-glucose) using 
two-dimensional nuclear magnetic resonance (NMR)-based metabolomics in 
293T cells. The metabolism of glycine from glucose was found to be highly 
enriched; 13C-glycine enrichment was nearly commensurate with that of 13C-
lactate, a hallmark of the Warburg effect 45. The second study used a pooled 
shRNA library against metabolic enzymes and transporters to screen for genes 
necessary for growth of human MCF10DCIS.com cells injected into mouse 
mammary fat pads 44. Both studies then combined their analyses with published 
genomic somatic copy-number alterations (SCNA) from 3,131 cancer samples 
consisting of tissue specimens and cancer cell lines 46. PHGDH was found to be 
amplified in a peak region of chromosome 1p12 in 16% of the samples 44,45. 
Furthermore, some of the amplifications were focal and contained no known 
oncogene. Amplification was particularly prevalent in melanomas and breast 
cancers. Breast cancer and melanoma cell lines harboring PHGDH 
amplifications, or overexpressing PHGDH independent of amplification, were 
shown to be highly sensitive to PHGDH knockdown, while lines that expressed 
little to no PHGDH were insensitive 44,45. These results suggested that PHGDH 
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overexpression leads to a dependency on, or addiction to, de novo serine 
synthesis. In breast cancer, PHGDH expression has been shown to correlate 
with both the triple negative and basal subtypes, increased metastatic potential, 
and shorter patient survival suggesting that targeting PHGDH in amplified 
cancers may be therapeutically advantageous 44,45,47.  
The pro-tumorigenic role of serine synthesis is not limited to melanomas 
and breast cancer. Indeed, profiling of de novo serine synthesis in a large panel 
of non-small cell lung cancer (NSCLC) cell lines showed that high pathway 
activity was independent of amplification and instead regulated by the 
transcription factor NRF2, an oncogene frequently mutated in NSCLC 41. While 
serine synthesis activity in NSCLC lines was heterogeneous, lines with high 
pathway activity were sensitive to PHGDH knockdown. Furthermore, expression 
of serine synthesis genes and SHMT2 correlated with poor patient survival. De 
novo serine synthesis was critical for NSCLC cells to maintain glutathione, purine 
nucleotide, and dTMP levels consistent with the known anabolic functions of 
serine 41.  
In addition to NRF2, the histone H3 lysine methyltransferase G9A and the 
transcription factors c-Myc and ATF4 have been shown to positively regulate 
serine biosynthesis gene expression suggesting additional mechanisms for 
amplification independent overexpression in cancer 41,48-50. Notably, serine 
biosynthesis genes have been shown to be regulated by ATF4 in a number of 
different cell types suggesting that it is a general mechanism for inducing serine 
biosynthesis consistent with the established role of ATF4 in the amino acid 
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depletion response 50-52 41. Interestingly, serine is involved in a regulatory 
feedback loop with pyruvate kinase M2 (PKM2). Serine binds to PKM2 
allosterically to activate it and reduce the funneling of 3-PG into serine synthesis 
53,54. Conversely, excessive PKM2 activation can induce serine auxotrophy and 
ATF4 induction suggesting that pyruvate kinase M1 expressing cells may have a 
more limited serine synthesis capability 50,53,55.  
NADPH powers reductive biosynthesis and cellular antioxidant defenses, 
and is therefore critically important for cellular proliferation and maintenance of 
redox homeostasis,5,33,56. Traditionally, the oxidative pentose phosphate pathway 
is thought to be the major provider of NADPH with malic enzyme sometimes 
being important 11,57. In NSCLC cell lines, however, PHGDH knockdown was 
shown to deplete cellular NADPH levels specifically in PHGDH overexpressing 
cells suggesting an additional means by which PHGDH can promote tumor 
growth 41. Although the exact mechanism by which serine enables NADPH 
production is not yet clear, recent evidence suggests that oxidation of serine 
derived methylene units via the folate cycle produces significant amounts of 
NAPDH 58,59,60. Interestingly, using ectopic mutant IDH expression as a 
compartment specific NADPH reporter suggested that the oxidation of serine 
derived CH2-THF via the folate cycle contributes to mitochondrial NADPH 
production rather than cytosolic NADPH production 59. Serine flux to 
mitochondrial folate metabolism has been suggested to be important in mitigating 
mitochondrial oxidative stress under hypoxia since HIF1 induces expression of 
SHMT2 in a Myc dependent manner to prevent accumulation of reactive oxygen 
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species and maintain GSH levels 60. Thus, the recent realization that NADPH is 
also a downstream product of serine expands the scope of the anabolic 
processes dependent on serine and suggests another way in which PHGDH 
overexpression can be pro-tumorigenic. Indeed, the importance of ROS and 
NADPH metabolism for tumorigenesis is well established 56,61.  
While the anabolic functions of serine suggest that increased serine 
synthesis might enable tumorigenesis by passively supporting biomass 
production, some evidence suggests that PHGDH may be playing a more active 
role in tumorigenesis. MCF-10A cells, an immortalized but non-transformed 
human mammary epithelial cell line, grown in Matrigel reconstituted basement 
membrane form polarized, growth-arrested, hollow acinus-like spheroids that 
mimic in vivo glandular architecture. Provocatively, overexpressing PHGDH in 
MCF-10A cells disrupted acini polarity and resulted in a luminal filling phenotype 
indicating a failure of extracellular matrix detached cells to undergo apoptosis, 
which is suggestive of transformation 45. In addition, overexpressing PSAT1 and 
PSPH in 3T3 cells allowed 3T3 cells to form tumors when injected into mice 62. 
There is precedence for metabolic enzymes playing an active role in 
tumorigenesis. The TCA cycle enzymes fumarate hydratase (FH) and succinate 
dehydrogenase (SDH) follow a classical familial tumor suppressor paradigm with 
loss of heterozygosity (LOH) 63. Typical of an oncogene, only a handful of IDH1/2 
mutations are known and confer the same neomorphic activity 64. 
Mechanistically, FH, SDH, and IDH mutations are thought to induce epigenetic 
deregulation conducive to transformation 63,65. How PHGDH could have 
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pleiotropic effects sufficient to induce transformation is still difficult to imagine. 
Thus, whether PHGDH is a bona-fide oncogene remains to be determined, but 
these results combined with the occurrence of focal PHGDH amplifications and 
oncogene induced PHGDH overexpression suggests that, at a minimum, serine 
synthesis can play an important role in supporting tumorigenesis.  
While it would be tempting to conclude that enhanced serine synthesis is a 
general hallmark of cancer akin to the Warburg effect, this is likely not the case. 
Nearly a third of the cell lines profiled in the large NSCLC panel had low serine 
biosynthetic activity 41. Given that many cancer cell lines require serine import, 
and that the vast majority of the NCI-60 panel consume more serine from the 
media than they release, it is more likely that serine import is a common feature 
across cancer cell lines in culture and that only a subset of lines are addicted to 
de novo serine synthesis 43 66 44,47.  
 
Potential Mechanisms for Addiction to De Novo Serine Synthesis 
 
The mechanism through which PHGDH overexpressing cells become 
addicted to serine synthesis remains unclear. It is surprising that PHGDH 
overexpressing cells are sensitive to PHGDH knockdown given the presence of 
serine in tissue culture media 17. There are at least three models that could 
account for the failure of extra-cellular serine to rescue PHGDH knockdown. The 
first model resolves to a kinetic issue where the rate of serine uptake via amino 
acid transporters is insufficient to compensate for loss of serine biosynthetic 
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activity. However, this seems unlikely because in a PHGDH amplified breast 
cancer line, MDA-MB-468, less than 20% of intracellular serine is derived from 
de novo synthesis 67.  
The second model is that cancer cells become addicted to the de novo 
serine synthesis pathway not because it provides serine, but because flux 
through the phosphoserine pathway provides another metabolite. For example, it 
has been suggested that 50% of the !-ketoglutarate pool in MDA-MB-468 cells 
comes from the PSAT1 reaction and that this is an important anaplerotic flux for 
the TCA cycle 44. This is surprising, however, because !-ketoglutarate is usually 
thought to be produced by transaminases and glutaminolysis 9 68. Moreover, our 
attempts to rescue PHGDH knockdown with cell permeable !-ketoglutarate 
derivatives have been unsuccessful (unpublished). Interestingly, as an error 
reaction, PHGDH has been reported to produce the oncometabolite D-2-
hydroxyglutarate from the NADH dependent reduction of !-ketoglutarate 69. 
Again, however, this seems an unlikely mechanism because in PHGDH amplified 
MDA-MB-468 cells, PHGDH dependent D-2-hydroxyglutarate production is only 
on the order of 40µM whereas millimolar levels of D-2-hydroxyglutarate are 
observed in patients and cell lines with IDH1/2 mutations 64,67,70. Moreover, in the 
PHGDH amplified cell line Hcc70, PHGDH knockdown inhibits growth but does 
not reduce basal D-2-hydroxyglutarate levels 67.  
A third model for the necessity of de novo serine synthesis despite the 
presence of serine in tissue culture media is that the extra-cellular and intra-
cellular serine pools are somehow distinct. Mechanistically, this could be 
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achieved via the formation of protein complexes that funnel de novo serine 
synthesis flux into specific downstream pathways or specific organelles (eg. 
mitochondria versus cytoplasm). Both complex mediated funneling and 
compartment specific metabolism are well established. For example, the 
purinosome is a complex that groups all six enzymes needed to synthesize 
inosine monophosphate (IMP), the purine precursor to AMP and GMP, from 
phosphoribosyl pyrophosphate (PRPP) 71. Interestingly, a nuclear complex for 
TMP synthesis composed of thymidylate synthase, SHMT1 or SHMT2!, and 
dihydrofolate reductase has been reported 72,73. While the association of de novo 
serine synthesis with the thymidylate synthase complex would fit well with the 
importance of serine synthesis for nucleotide production, nuclear localization of 
PHGDH has not been observed; furthermore, one would presume that cytosolic 
serine, imported from the extra-cellular space or synthesized from glucose, could 
simply diffuse to the nucleus 74.  
While the mechanism for PHGDH addiction remains unclear there is an 
increasing body of work that links serine to the production of NADPH via the 
folate cycle suggesting that avenues of research pursuing the contribution of de 
novo serine synthesis to NADPH and folate metabolism may be a fruitful path of 
inquiry 58,60,75. Indeed, beyond the ability of PHGDH overexpressing cells to grow 
in serine free media, the only phenotype that has been shown to distinguish 
PHGDH overexpressing cells from non-overexpressing cells is a decrease in 
NADPH following PHGDH knockdown in the former 41.  
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Chapter 2: Identification of a Small Molecule Inhibitor PHGDH  
 
 
Abstract: 
 
Cancer cells reprogram their metabolism to promote growth and 
proliferation. The genetic evidence pointing to the importance of the amino acid 
serine in tumorigenesis is striking. The gene encoding the enzyme 3-
phosphoglycerate dehydrogenase (PHGDH), which catalyzes the first committed 
step of serine biosynthesis, is overexpressed in tumors and cancer cell lines via 
focal amplification and NRF2-mediated upregulation. PHGDH overexpressing 
cells are exquisitely sensitive to genetic ablation of the pathway. Here, we report 
the discovery of a novel and selective small molecule inhibitor of PHGDH, CBR-
5884, identified by screening a library of 800,000 drug-like compounds. CBR-
5884 inhibited de novo serine synthesis in cancer cells and was selectively toxic 
to cancer cell lines with high serine biosynthetic activity. Biochemical 
characterization of the inhibitor revealed that it was a non-competitive inhibitor 
that showed a time dependent onset of inhibition and disrupted the 
oligomerization state of PHGDH. The identification of a small molecule inhibitor 
of PHGDH not only enables thorough preclinical evaluation of PHGDH as a 
target in cancers, but also provides a tool with which to study serine metabolism.  
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Introduction: 
 
Serine is required for a plethora of anabolic processes including the 
synthesis of lipids, protein and nucleic acids 24-26. At the cellular level, serine can 
be imported from the extracellular space via amino acid transporters 21,76. 
Alternatively, serine can be synthesized from glucose via the phosphoserine 
pathway 18. De novo synthesis proceeds from the glycolytic intermediate 3-
phosphoglycerate (3-PG) via three sequential enzymatic reactions (Figure 1.1), 
the first of which is catalyzed by the NAD+ dependent enzyme 3-
phosphoglycerate dehydrogenase (PHGDH) 17. For decades, it has been known 
that cancer cells have enhanced serine synthesis, which contributes to 
nucleotide synthesis 38,40. Recently, focal amplifications of the gene encoding 
PHGDH have been reported, particularly in breast cancers and melanomas 44-46. 
Additionally, KEAP1 and NRF2 mutant non-small cell lung cancers (NSCLC) 
overexpress PHGDH 41. Proliferation of PHGDH amplified cancer cell lines, and 
other lines that overexpress PHGDH without amplification, is inhibited by PHGDH 
knockdown. In contrast, lines that express little PHGDH are resistant to shRNA 
mediated ablation of the pathway presumably because serine import suffices 
44,45. A detailed mechanistic understanding of why some cancer cells are 
addicted to serine synthesis despite the availability of extracellular serine for 
import remains unclear. Interestingly, in triple negative breast cancer (TNBC) and 
NSCLC, PHGDH amplification and overexpression are associated with more 
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aggressive disease 41,44,45,47. Thus, PHGDH inhibitors as a targeted therapy for 
these tumor types represent an exciting clinical opportunity.  
 The studies herein detail our efforts in identifying small molecule inhibitors 
of PHGDH. We reasoned that a PHGDH inhibitor would have the benefits of not 
only providing a tool compound with which to study the biology of serine 
synthesis, but also enable thorough preclinical evaluation of PHGDH as a target 
in cancers. We developed an in vitro assay for PHGDH amenable to high 
throughput screening and screened a library of 800,000 small molecules for 
inhibitors of PHGDH. A cell-based assay for serine synthesis was used to identify 
a lead, CBR-5884, that was active in cells. CBR-5884 selectively inhibited the 
proliferation of melanoma and breast cancer lines that have a high propensity for 
serine synthesis, but had no effect on lines that rely on extra-cellular serine 
uptake. Mechanistically, CBR-5884 was found to be a noncompetitive inhibitor, 
showed a time dependent onset of inhibition, and disrupted the oligomerization 
state of PHGDH.  
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Results: 
 
Developing an in vitro assay for PHGDH 
 
In order to screen for inhibitors of PHGDH an in vitro assay for PHGDH 
needed to be developed. Initially, recombinantly expressed PHGDH and the 
downstream enzyme PSAT1 were incubated with their substrates NAD+, 3PG, 
and glutamate, and PHGDH activity was monitored by following the intrinsic 
fluorescence of the NADH produced (Figure 2.1 and 2.2). PSAT1 was included in 
the assay to prevent product inhibition of PHGDH. Given that the thermodynamic 
equilibrium for the PHGDH reaction lies heavily towards 3-PG 18, high 
concentrations of glutamate (30mM) were included in the assay to drive the 
PHGDH reaction forward.  
 
 
 
Figure 2.1. Schematic for the in vitro PHGDH enzymatic assay. 
Recombinantly expressed PHGDH and PSAT1 are incubated with their 
substrates NAD+ and glutamate. The reaction is initiated by the addition of 3-PG 
and NADH fluorescence (340/460nm Ex/Em) is monitored over time. 3-PG: 3-
phosphoglycerate; NAD+: nicotinamide adenine dinucleotide; !KG: alpha-
ketoglutarate; p-Pyr: phosphohydroxypyruvate; p-Ser: phosphoserine. 
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Figure 2.2. Progress curve for the PHGDH reaction. PHGDH activity is 
monitored by following the increase in NADH fluorescence (340/460nm Ex/Em) 
using the in vitro assay developed. 3-PG: 3-phosphoglycerate. RFU: relative 
fluorescence units.  
 
 
An understanding of the Michaelis-Menten constants (Km ) of each 
substrate is important in order to design the screening assay conditions. 
Competitive inhibitors can only bind to the free enzyme (no substrate bound) and 
therefore the ability to identify them decreases with an increasing [S] / Km ratio. In 
contrast, uncompetitive inhibitors bind to the enzyme substrate complex (ES). 
Thus, as the [S] / Km ratio increases, the likelihood of an ES complex increases, 
which facilitates uncompetitive inhibitor binding. It has been shown that screening 
at the substrate Km provides the best compromise for the assay to detect both 
competitive and non-competitive inhibitors 77. The Km constants for PHGDH were 
determined by titrating each substrate, NAD+ or 3-PG, one at a time, while 
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holding the remaining substrate at a fixed concentration and in excess such that 
the PHGDH reaction became pseudo first order with respect to the substrate 
being titrated. The Km was determined to be 60± 10µM with respect to NAD+ and 
1.4± 0.6µM with respect to 3-PG (Figure 2.3). The Km for NAD+ was in good 
agreement with the literature value reported for chicken liver PHGDH (60µM) 78.  
 
 
 
 
Figure 2.3. Michaelis-Menten plots for each PHGDH substrate. One at a time, 
each PHGDH substrate was titrated while holding the other substrate constant 
and in excess. The initial reaction rates were determined and plotted as a 
function of substrate concentration and the data were fit using non-linear 
regression to a Michaelis-Menten model. 3-PG: 3-phosphoglycerate; NAD+: 
nicotinamide adenine dinucleotide. Km  values are the average of three replicates. 
Error is given as ± 1SD.  
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 Inhibitors effectively decrease the fraction of active enzyme. Thus, in order 
to identify inhibitors, the initial rate of the enzymatic reaction needs to be linearly 
dependent on the PHGHD concentration otherwise binding of an inhibitor to 
PHGDH may not translate into a detectable decrease in signal. Moreover, given 
that the PHGDH reaction is coupled to the PSAT1 reaction, the rate of the 
PHGDH reaction may be limited by the rate of the downstream PSAT1 reaction. 
Running the screen under conditions in which the PSAT1 reaction is rate limiting 
would favor the identification of inhibitors targeting PSAT1 instead of PHGDH. 
Titrating PHGDH in the presence of NAD+ at 1 Km and 3-PG at 100 Km in the 
presence of 1850nM PSAT1, showed that the reaction was linearly dependent on 
PHGDH from 20nM to 150nM PHGDH (Figure 2.4). The Km for 3-PG (1.4± 
0.6µM) was so low that it was impossible to efficiently detect NADH fluorescence 
when the assay was performed at the 3-PG Km and a concentration200-fold the 
Km had to be used (data not shown). Thus, 70nM PHGDH was selected as the 
optimal concentration for the given assay conditions.  
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Figure 2.4. Linear dependence of the initial reaction rate on PHGDH 
concentration. Two-fold serial dilution of PHGDH in the presence of 1850nM 
PSAT1, 200 times the 3-PG Km, and 1 times the NAD+ Km. Initial rates are plotted 
as a function of PHGDH concentration. The reaction rate is linearly dependent on 
PHGDH concentration from 18nM to 150nM. A representative example from 3 
independent experiments is shown.   
 
 
While assays measuring NADH fluorescence are amenable to high-
throughput chemical screening, they are not ideal. A significant number of 
compounds in chemical libraries fluoresce at 460nm and would therefore 
interfere with the assay readout. In order to improve signal to noise ratio, since 
NADH is a relatively week fluorophore, and decrease the likelihood of compound 
interference, the reaction was coupled to diaphorase (Figure 2.5). Diaphorase 
can use the NADH produced upon PHGDH turnover to reduce resazurin to a 
potent fluorophore, resorufin. When the in vitro PHGDH assay was coupled to 
diaphorase, the progress curve showed a lag phase of approximately 10 minutes 
that was not seen in the PHGDH reaction progress curve suggesting that the 
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diaphorase reaction was slower than the PHGDH reaction (compare Figure 2.2 
to Figure 2.6). Titrating resazurin in the diaphorase coupled PHGDH assay 
revealed that diaphorase was subject to substrate inhibition at high resazurin 
concentrations indicating the cause of the lag phase in the coupled reaction 
(Figure 2.7). At 0.1mM resazurin, the kinetics of the diaphorase coupled PHGDH 
reaction progress curved mirrored that of the PHGDH reaction monitored via 
NADH fluorescence. Thus, 0.1mM resazurin was selected for future assays. 
However, it was noted that even in the no diaphorase control, the resorufin signal 
increased overtime (Figure 2.7). This was problematic for the high throughput 
screen as it decreased the signal to noise ratio of the assay over time and would 
make it difficult to compare results across different compound screening assay 
plates. It was noted that when the diaphorase-coupled reaction was quenched 
with 50% methanol, the diaphorase independent reduction of resazurin still 
proceeded at the same rate indicating that the process was non-enzymatic (data 
not shown). Indeed, the dithiothreitol (DTT) included in the assay buffer was 
found to spontaneously reduce resazurin. Omitting DTT from the assay buffer 
was sufficient to abrogate the time dependent increase in background 
fluorescence (Supplementary Figure 2.1). Thus, DTT was removed from the 
assay buffer for the high throughput screen.  
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Figure 2.5. In vitro PHGDH assay coupled to diaphorase. Diaphorase couples 
the NADH produced upon PHGDH turnover to the reduction of resazurin to 
fluorescent resorufin concomitantly recycling the NAD+. Resorufin fluorescence is 
a proxy for PHGDH activity. 
 
 
 
 
 
Figure 2.6. Progress curve for PHGDH reaction coupled to diaphorase. 
Coupling the PHGDH assay to diaphorase results in a lag phase of ~10min to the 
progress curve. Resorufin fluorescence (550/585nm Ex/Em) was monitored over 
time. A no diaphorase control was included to ensure that the signal was specific 
to the diaphorase reaction. 
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Figure 2.7. Substrate inhibition of diaphorase and spontaneous reduction 
of resazurin. (A) Titrating the resazurin concentration used for the diaphorase 
coupled PHGDH assay revealed that the lag phase was due to substrate 
mediated inhibition of diaphorase. (B) Omitting diaphorase from the coupled 
reactions reveals resazurin is spontaneously reduced leading to an increasing 
background signal over the course of the assay.  
 
 
Given that NAD+ dependent dehydrogenases, such as PHGDH, are a 
large family of enzymes, we were concerned that screening at the Km of NAD+ 
would identify compounds that bound competitively to the NAD+ pocket and that 
such compounds would have significant off target activity on other 
dehydrogenases. Thus, after verifying that the reaction rate was still linearly 
dependent on the PHGDH concentration at increased NAD+ concentrations, we 
decided to increase the NAD+ concentration used in the screening assay to 8mM. 
Bromopyruvate (BrPYR) has been reported to be a nonspecific inhibitor of 
PHGDH and was thus selected as a positive control for inhibition in the high 
throughput screening assay 78. A progress curve for the finalized diaphorase 
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coupled PHGDH assay miniaturized to 384-well plate format is presented (Figure 
2.8). The assay was approximately linear over the first 30 minutes. The high 
throughput assay was to be performed in a single point format. Thus, we opted 
for stopping the reaction with the addition of 50% methanol following a 20-minute 
reaction corresponding to a signal to background ratio of 3 (Figure 2.8). 
Resorufin fluorescent signal was shown to be stable for at least five hours after 
stopping the reaction (data not shown). In a pilot experiment mimicking the 
screening protocol, the Z-factor for the screening assay was determined to be 
0.66 indicating a high quality assay (Figure 2.8) 79. Thus, we were confident the 
assay developed could be used for a high-throughput screening campaign. The 
final components of the optimized assay are presented in Table 1.  
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Figure 2.8. PHGDH assay miniaturization and Z-factor. (A) Progress curve for 
diaphorase coupled PHGDH assay in 384-well plate format with bromopyruvate 
(BrPYR) treatment (0.5mM) or vehicle control treatment (DMSO). At a 20 minute 
endpoint, the assay has a signal to background ratio (S/B) of three. (B) Z-factor 
for the 384 well plate format assay. Three assay plates of negative control wells 
(vehicle treated) and inhibitor positive control wells (bromopyruvate treated) were 
screened at a 10µL or 50µL final reaction volume using the automated high 
throughput screening protocol. The Z-factor for each assay volume was 
calculated from the mean and standard deviations of the positive and negative 
control wells.  
 
 
Table 1. Summary of PHGDH assay conditions for screening.  
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Screening for small molecule inhibitors of PHGDH 
 
The diaphorase coupled PHGDH assay was further miniaturized to 1536 
well plate format with a Z-factor of >0.75 indicating a high quality assay. A library 
of 800,000 structurally diverse compounds with drug-like properties and known 
biological actives (kinase inhibitors, epigenetic modifiers, natural products) was 
screened in single point format at 13µM (Figure 2.9). Setting a hit threshold Z 
score of -3, corresponding to at least 50% PHGDH inhibition, gave a 0.5% hit 
rate yielding 3,906 hits. Putative hits were re-assayed in triplicate and counter 
screened against diaphorase to rule out false positives targeting diaphorase. The 
counter screen eliminated 3,498 compounds giving 408 PHGDH inhibitors 
(Figure 2.10).  
 
 
Figure 2.9. Z-score plot for a 800,000 compound library screened against 
PHGDH. Each point on the graph represents the Z-score of a single compound. 
A negative Z-score indicates inhibition and a positive one activation. Setting a 
threshold Z score of -3, corresponding to at least 50% PHGDH inhibition, gave a 
0.5% hit rate yielding 3,906 hits. 
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Figure 2.10. Screen triaging strategy. Setting a Z-score threshold of -3 gave 
3,906 putative hits. After counter-screening against diaphorase to rule out false 
positives and confirming activity against PHGDH, 408 compounds remained. 
Selected compounds were profiled against a panel of metabolic NAD(P)+ 
dehydrogenases to ascertain selectivity for PHGDH. 
 
 
A triaging strategy based on hit potency and selectivity was designed 
(Figure 2.10). We reasoned that inhibitors specific to PHGDH would minimize 
general cellular toxicity compared to compounds that hit a variety of 
dehydrogenases. Thus, for commercially available hits (45 compounds) half 
maximal inhibitory concentrations (IC50) were determined against a panel of 
NAD(P)+ dependent dehydrogenases that included PHGDH, isocitrate 
dehydrogenase (IDH1), malate dehydrogenase (MDH1), and 3!-hydroxysteroid 
dehydrogenase (3!-HSD). Compounds at least 4-fold more selective for PHGDH 
were progressed for further analysis. Based on this triaging, seven of the most 
!
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potent PHGDH inhibitors were selected as lead compounds for evaluation in cell-
based assays; selected structures are shown (Figure 2.11, Table 2). A number of 
these compounds are likely to target sulfhydryl groups and may therefore react 
with a PHGDH cysteine residue. For example, both CBR-5807 and CBR-6936 
contain sulfhydryl reactive disulfide centers that are unstable. Interestingly, CBR-
5807 (disulfiram) is an approved drug dosed in humans to treat alcoholism and 
known to inhibit aldehyde dehydrogenase by reacting with sulfhydryl groups 80.  
 
 
 
Figure 2.11. Sample structures of PHGDH inhibitors identified. CBR-5807 is 
an approved drug, disulfiram, that inhibits aldehyde dehydrogenase by targeting 
sulfhydryl groups.  
 
 
Table 2. In vitro selectivity profiling of PHGDH inhibitors. For each 
compound, enzyme IC50 was normalized to that of PHGDH to indicate 
relative compound selectivity. 
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CBR-5884 inhibits serine synthesis in cells 
 
We determined whether any of our seven leads inhibited serine synthesis 
in cancer cells. To do so, we turned to gas chromatography-mass-spectrometry 
(GCMS) with uniformly carbon-13 labeled glucose (13C6-glucose) tracing. Given 
the isotopic enrichment of serine, it is possible to decouple newly synthesized 
serine from extracellular serine or serine that was synthesized prior to tracer 
addition. Newly synthesized serine has a mass-shift of 3 (M+3) due to the 
incorporation of glucose-derived 13C via 3-PG. We first investigated the kinetics 
of phosphoserine pathway labeling. While 3-PG labeling quickly saturated at 
~90%, serine labeling plateaued around 6h with ~65% of the serine pool being 
13C labeled  (Figure 2.12). Consistent with prior reports, both M+0 and M+3 
phosphohydroxypyruvate was undetectable by GCMS possibly due to low 
abundance and/or poor stability (data not shown) 69. The plateau phase in serine 
labeling likely reflects exchange between intra- and extra-cellular serine pools 81.  
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Figure 2.12. Kinetics of phosphoserine pathway labeling. 13C6-glucose was 
added to Carney cells grown in serine free media at time t = 0 and cells were 
labeled for the indicated time points. Polar metabolites were extracted and 
analyzed by GCMS. (A) Glucose-derived 3-PG (M+3) and (B) glucose-derived 
serine (M+3) relative to total 3-PG or serine levels are plotted. Each point 
indicates an independent experiment. 
 
 
With an understanding of serine labeling kinetics, we designed a 13C6-
glucose tracing assay to acutely interrogate the effects of compounds on serine 
synthesis (Figure 2.13). Assaying serine synthesis with a 3-hour compound 
treatment was preferred to longer treatments to guard against false positives that 
decrease serine labeling by an indirect effect, such as generally compromising 
cellular viability. Among our lead compounds, CBR-5884 was able to decrease 
de novo serine synthesis by 30%; the remaining compounds had little effect 
(Figure 2.13). 
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Figure 2.13. CBR-5884 inhibits serine synthesis in cells. (A) Acute inhibitor 
treatment assay schematic. Carney cells are pre-treated with drug at 30µM for 1h 
prior to initiating 13C6-glucose labeling for 2h still in the presence of drug. Polar 
metabolites are harvested and analyzed by GC-MS. (B) The ability of the 7 lead 
PHGDH inhibitors to block serine synthesis was assayed as in (A). Only CBR-
5884 decreased glucose derived serine labeling. M+3 serine levels relative to 
total serine levels are plotted. Asterisks indicate significant differences vs. DMSO 
treatment (p < 0.05, t-test, n " 3). Error is given as ± 1SD. 
 
 
 The dose at which CBR-5884 had an effect on serine labeling was 
consistent with the in vitro biochemical IC50 of 33 ±12µM for PHGDH (Figure 
2.14). At such concentrations, CBR-5884 had no effect on two other NAD+ 
dependent dehydrogenases, lactate dehydrogenase (LDH) and MDH1 (Figure 
2.14, Figure 2.17). Importantly, under the acute treatment time period used in the 
labeling assays, CBR-5884 was not generally cytotoxic at concentrations up to 
40µM as determined by two independent cellular viability assays (Figure 2.15). 
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Hence, decreases in serine labeling are a direct effect of CBR-5884 mediated 
PHGDH inhibition and not a consequence of general cellular toxicity.  
 
 
Figure 2.14. In vitro IC50 of CBR-5884 on PHGDH and LDH. (A) In vitro IC50 
assays for PHGDH and lactate dehydrogenase, LDH. Initial rates of the 
enzymatic reaction (Vi) at the indicated CBR-5884 concentration normalized to 
that of the DMSO control (Vo) are plotted. The mean IC50 ± 1SD is given from 
three replicate experiments. 
 
 
Figure 2.15. CBR-5884 is not generally toxic to cells. Carney cells were 
treated with a serial dilution of CBR-5884 for 3 hours to mimic the acute 13C6-
glucose labeling assay conditions and cellular reducing potential and ATP levels 
were determined using an (A) Alamar blue or (B) ATPGlo assay, respectively. 
Error is given as mean ± 1SD (n " 3). 
B A 
Alamar Blue ATP-Glo  
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 We resynthesized CBR-5884 in house and performed a dose response 
experiment for CBR-5884 employing the same acute treatment method as 
above. Serine labeling was significantly decreased at 30µM and trended towards 
a decrease at 15µM (Figure 2.16). Importantly, perturbations in labeling were 
specific to serine in that neither the PHGDH substrate, 3-PG, nor the end 
products of glycolysis, pyruvate and lactate, was affected (Figure 2.16). We 
further confirmed that glycolytic metabolites were unperturbed by CBR-5884 
treatment using LC-MS/MS to interrogate a greater panel of metabolites (Figure 
2.16). Thus, changes in serine labeling are a direct effect of CBR-5884 mediated 
PHGDH inhibition and not a consequence of changes in PHGDH substrate levels 
or general perturbations in glycolytic flux. The absence of an effect on lactate 
labeling was consistent with the in vitro data showing that CBR-5884 does not 
inhibit LDH under the drug concentrations used. In sum, the data argue that 
CBR-5884 is able to selectively inhibit serine synthesis in cells. 
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Figure 2.16. CBR-5884 inhibits serine synthesis in cells without perturbing 
glycolysis. (A) Dose response experiment on Carney cells using CBR-5884 
synthesized in house following the same acute labeling assay as in Figure 2.13 
but monitoring a panel of phosphoserine pathway and glycolytic metabolites. (B) 
Glycolytic metabolite levels for Carney cells pre-treated with DMSO or CBR-5884 
(30µM) for 4 hours and then labeled for 2 hours with U-13C-glucose under 
continued DMSO or drug treatment. Polar metabolites were extracted and 
analyzed by LC-MS/MS. The fractional labeling (M+3 metabolite level relative to 
total metabolite level) is plotted for each indicated metabolite Error is given as ± 
1SD, n " 3. F6P: fructose-6-phosphate; FBP: fructose-1,6-bisphosphate; DHAP: 
dihydroxy-acetone-phosphate; G3P: glyceraldehyde-3-phosphate; BPG: 1,3-
bisphosphoglycerate or 2,3-bisphosphoglycerate (isotopomers); 3PG: 3-
phosphoglycerate; PEP: phosphoenolpyruvate. 
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Given that CBR-5884 is an ethyl ester and therefore susceptible to 
intracellular esterases, we investigated whether the carboxylic acid derivative of 
the parent molecule was still active against PHGDH; were the acid less active, it 
would likely decrease the efficiency of targeting PHGDH in situ. Parent and acid 
derivatives were equally potent against and selective for PHGDH in vitro 
suggesting that intra-cellular de-esterification is unlikely to affect CBR-5884 
activity (Figure 2.17).  
 
 
 
Figure 2.17. In vitro IC50 of CBR-5884 and acid derivative on PHGDH and 
MDH1. In vitro enzymatic assay for malate dehydrogenase 1 (MDH1) or PHGDH 
titrating CBR-5884 (parent) or the carboxylic acid derivative (acid). Structures of 
parent and acid are provided for comparison. Initial rates (Vi) normalized to the 
DMSO control rate (Vo) are plotted. 
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CBR-5884 selectively inhibits the proliferation of cancer cells with a high 
propensity for serine synthesis 
 
 We wanted to establish a system to test the ability of CBR-5884 to inhibit 
PHGDH-dependent cancer cell proliferation. Thus, we decided to first evaluate 
the ability of a panel of breast and melanoma cell lines to proliferate in serine 
replete or deplete media as a proxy for serine biosynthetic activity. Breast lines 
were selected based on PHGDH expression according to the Cancer Cell Line 
Encyclopedia (CCLE) data; no data were available for the melanoma lines 
(Figure 2.18)82. PHGDH levels were validated by western blotting (Figure 2.19). 
In the breast cancer cell lines, PHGDH expression levels appeared to be a good 
predictor of protein levels consistent with the report that in a large panel of non-
small cell lung cancer cell lines PHGDH expression correlates strongly with 
serine biosynthetic activity 41. Removing extracellular serine had no effect on the 
proliferation of the four high PHGDH expressing breast cancer lines (MDA-MB-
468, MDA-MB-436, HCC70, Hs578T) or the PHGDH high expressing melanoma 
line WM266-3 (Figure 2.20). All four breast cancer lines cluster in the top quartile 
of the CCLE data set for PHGDH expression (Figure 2.18); MDA-MB-468, 
HCC70, and WM266-3 cells harbor PHGDH amplifications 44,45. In contrast, 
serine depletion almost completely abrogated proliferation of low PHGDH 
expressing lines: MDA-MB-231, MCF-10A, and Gak (Figure 2.20). Interestingly, 
although Carney cells are sensitive to extracellular serine depletion, they can 
(%!
adapt and resume proliferation as evidenced by increased PHGDH protein levels 
upon prolonged serine depletion (Figure 2.21).  
 
 
Figure 2.18. PHGDH expression across CCLE panel. Relative PHGDH 
expression levels across a panel of 1036 cell lines obtained from the CCLE data 
set. Selected breast cancer lines used for drug proliferation assays are 
highlighted in orange. Hcc70 and MDA-MB-468 cells are known to harbor 
PHGDH amplifications. No CCLE expression data were available for the 
melanoma lines.  
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Figure 2.19. PHGDH protein levels across a panel of breast and melanoma 
lines. Western blot for PHGHD on panel of (A) breast and (B) melanoma lines 
grown in serine containing media; 2 lanes per cell line with each lane loaded with 
independent cell lysates. Hcc70, MDA-MB-468, and WM266-3 are PHGDH 
amplified. 
 
 
 
 
Figure 2.20. Proliferation of breast and melanoma lines in serine replete or 
serine deplete media. (A) Breast and (B) melanoma lines were grown in serine 
replete (+SER) or serine deplete (-SER) media for 3-5 days. Relative cell 
numbers were determined via crystal violet staining or a Cyquant assay. 
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Figure 2.21. Carney cells adapt to serine deprivation by upregulating 
PHGDH protein levels. Western blot for WM266-3 and Carney cells grown in 
serine replete (+) or serine deplete (-) media; 2 lanes per cell line with each lane 
loaded with independent cell lysates. 
 
 
Given that the ability to proliferate in the absence of extra-cellular serine is 
indicative of a high propensity for serine synthesis, we hypothesized that such 
lines should be sensitive to CBR-5884. Conversely, lines that cannot grow in 
serine free media have a low propensity for serine synthesis and should 
therefore be resistant to PHGDH inhibition. Treating the breast lines with CBR-
5884 in serine replete media inhibited growth of the four lines that grew without 
extra-cellular serine in a dose dependent manner with growth inhibition ranging 
from 35% to 60% at 30µM CBR-5884. The inhibitor had no effect on the three 
lines sensitive to serine withdrawal indicating that the inhibitor was selectively 
toxic to cells with high serine synthesis activity (Figure 2.22). We next asked 
whether removing serine from the media, to enhance the reliance on de novo 
serine synthesis, could sensitize cells to PHGDH inhibition. Indeed, serine 
depletion increased the efficacy of CBR-5884 in lines already sensitive under 
serine replete conditions as evidenced by an 80% to 90% decrease in 
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proliferation with 30µM CBR-5884 (Figure 2.22). Moreover, MCF7 cells, which 
were of intermediate sensitivity to serine withdrawal, and insensitive to drug 
under serine replete conditions, became partially sensitive to the inhibitor under 
serine deplete conditions.  
 
 
Figure 2.22. CBR-5884 selectively inhibits the proliferation of breast cancer 
lines that overexpress PHGDH. Proliferation assay for breast lines treated with 
CBR-5884 in (A) serine replete or (B) serine deplete media. MDA-MB-468 and 
Hcc70 are PHGDH amplified. MCF-10A is a non-transformed mammary epithelial 
cell line; other lines are cancer cell lines. MDA-MB-231 and MCF-10A lines were 
not included in –SER experiments because they are sensitive to serine 
withdrawal. Histograms depict mean ± standard error (n " 3). 
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Importantly, under serine replete conditions, PHGDH knockdown 
phenocopied the effects of CBR-5884 treatment in that the drug-sensitive lines 
were also sensitive to PHGDH knockdown (Figure 2.23). Furthermore, as with 
the drug treatments, growing cells in serine free media enhanced the growth 
inhibitory effect of PHGDH knockdown although decreased proliferation under 
serine starved conditions seemed more pronounced with CBR-5884 treatment 
than with PHGDH knockdown (Figure 2.23). Similar trends were observed for the 
melanoma panel in terms of both the selectivity of CBR-5884 for cells with a high 
propensity for serine synthesis and the increased efficacy under serine deplete 
conditions (Supplementary Figure 2.2 and 2.3). Given the prevalence of 
esterases and their role in drug metabolism, and that charged molecules often 
have poor plasma membrane permeability, we were concerned that de-
esterification of CBR-5884 in vivo might compromise activity on cells 83,84. 
Indeed, the acid derivative of compound 588-4 was not effective on MDA-MB-
468 cells and is therefore not a viable alternative to the parent compound 
(Supplementary Figure 2.4). 
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Figure 2.23. Knockdown of PHGDH in a panel of breast cancer lines.  
Proliferation assay for lines grown in (A) serine replete media (+SER) or (B) 
serine deplete media (-SER) with PHGDH knockdown (sh1 & sh2) or a 
nontargeting control (shGFP). MB-231 and MCF-10A lines were not included in –
SER experiments because they are sensitive to serine withdrawal. Histograms 
depict mean ± standard error (n " 3). 
 
 
In order to more deeply characterize the metabolic changes following 
CBR-5884 treatment we turned to LCMS based targeted metabolomics. We 
knocked down PHGDH using two different hairpins and compared the resultant 
metabolic profile to that following CBR-5884 treatment. Interestingly, the 
metabolic signature following CBR-5884 treatment was similar to that following 
B 
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either of the PHGDH knockdowns (sh1 and sh2) in that a majority of the 
significantly changed metabolites following CBR-5884 treatment overlapped with 
changes seen following PHGDH knockdown (Figure 2.24). Notably, the number 
of uniquely changed metabolites in the CBR-5884 treatment (20 metabolites) 
was less than the number of uniquely changed metabolites for sh1 (37 
metabolites) and similar to the unique changes for sh2 (16 metabolites) 
suggesting that the specificity of CBR-5884 for PHGDH is comparable to that of 
sh1 and sh2 in terms of metabolic effects. Importantly, decreases in serine and 
purine nucleotides (IMP, AMP, ADP, GMP, GDP, dAMP, dGDP), known 
downstream products of serine metabolism, were among the 47 metabolites 
commonly altered across the CBR-5884 treatment and both knockdowns, 
indicating that CBR-5884 has on target activity similar to that of the knockdowns 
(Figure 2.24) 41,43. Notably, glycerol-3-phosphate levels were increased in the 
CBR-5884 treatment whereas they were decreased in the two knockdown 
conditions, suggesting that the glycerol-3-phosphate dehydrogenase (GPDH) 
reaction that converts dihydroxyacetone phosphate (DHAP) to glycerol-3-
phosphate might be uniquely perturbed following CBR-5884 treatment (Figure 
2.24). Consistent with this, a decrease in DHAP was among the 20 metabolites 
that were uniquely perturbed by CBR-5884 treatment. Thus, we are currently 
investigating whether CBR-5884 has an off-target activity on GPDH.  
(,!
 
Figure 2.24. Comparison of metabolic changes following PHGDH 
knockdown versus CBR-5884 treatment. Polar metabolites were extracted 
from MDA-MB-468 cells following PHGDH knockdown (sh1 & sh2) or a 
nontargeting control (shGFP) knockdown and CBR-5884 treatment (24h, 30µM), 
and analyzed by targeted LCMS. Significantly altered metabolite levels for each 
group (sh1, sh2, or CBR-5884) were determined from comparison to shGFP 
control cells. (A) Venn diagram of all significantly changed metabolites. (B) Heat 
map depicting metabolic changes common to sh1, sh2 and CBR-5884 treatment. 
Blue: decrease; red: increase. * Serine. ** Glycerol-3-phosphate. 
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Analysis of CBR-5884 inhibition modality 
 
We sought to more deeply characterize the mechanism by which CBR-
5884 inhibits PHGDH. Inhibition constants (Ki) for CBR-5884 with respect to each 
substrate were determined. CBR-5884 inhibited PHGDH in a non-competitive 
mode with respect to both substrates, as evidenced by a decreasing Vmax with 
increasing CBR-5884 concentration. The inhibition constants were 50 ±20µM and 
50 ±3µM for 3PG and NAD+, respectively (Figure 2.25).  
 
 
 
Figure 2.25. Mechanisms of CBR-5884 inhibition. Inhibition constants (Ki) 
were determined by titrating (A) 3PG or (B) NAD+ while holding the other 
substrate constant at 4 different CBR-5884 concentrations and determining the 
initial reaction rate using a PHGDH assay. Plots were fit to a non-competitive 
model. Error is given as ± 1SD (n " 3) 
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We assessed whether there was any time dependence to the onset of 
inhibition by varying the time period for which drug and PHGDH were pre-
incubated before initiating the enzymatic reaction. CBR-5884 was progressively 
more potent with increasing pre-incubation time culminating in an IC50 of 7µM 
when drug and PHGDH were pre-incubated for 4 hours (Figure 2.26).  
 
 
Figure 2.26. CBR-5884 is a time dependent inhibitor of PHGDH. Time 
dependent inhibition was measured by preincubating drug and PHGDH for 0.5h, 
1h, or 4h as indicated prior to initiating the PHGDH reaction. Initial reaction rates 
(Vi) were determined and normalized to that of DMSO (Vo) and the IC50 
determined. The observed IC50 following the different preincubation times are 
given.  
 
 
Intrigued by the combination of a time dependent onset of inhibition and 
non-competitive inhibition, the latter suggesting that CBR-5884 might be binding 
to an allosteric pocket, we speculated that CBR-5884 could be affecting the 
PHGDH oligomerization state, where the time dependency of inhibition could 
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potentially stem from drug-induced conformational changes in PHGDH. To 
evaluate the PHGDH oligomerization state, we incubated PHGDH with drug and 
then cross-linked prior to SDS-PAGE. CBR-5884 shifted the PHGDH equilibrium 
from the tetrameric to the dimeric state (Figure 2.27). No such effect was 
observed with LDH, which is resistant to CBR-5884 mediated inhibition (Figure 
2.27). In order to determine whether disruption of the PHGDH tetramer was 
necessary for inhibition, we investigated whether CBR-5884 could still inhibit a 
truncated form of PHGDH, which lacks the C-terminal domain responsible for 
tetramerization. In agreement with the crystal structure for PHGDH3-314 (PDB: 
2G76), the cross-linking assay confirmed that the truncated PHGDH protein was 
a constitutive dimer (Figure 2.27). However, CBR-5884 still inhibited PHGDH3-314 
with a similar potency (IC50 20± 5µM) to that at which it inhibits the full-length 
protein suggesting that disruption of the tetramer is not essential for inhibition, at 
least in vitro (Figure 2.27). Together these results suggest that disruption of the 
tetramer might assist PHGDH inhibition, but is not necessary for inhibition. 
Finally, we investigated whether the time dependency of inhibition was due to the 
dissociation of the tetramer by varying the time for which PHGDH and drug were 
incubated prior to crosslinking (Figure 2.28). The tetramer to dimer ratio did not 
appear to be a function of drug and PHGDH preincubation time suggesting that 
the time dependency of inhibition does not stem from dissociation of the 
tetramer.  
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Figure 2.27. CBR-5884 disrupts the oligomerization state of PHGDH. (A) 
PHGDH or (B) LDH or (C) PHGDH3-314 were preincubated with CBR-5884 (0, 50, 
200, or 400µM) for 30min prior to crosslinking with BS3 (0.25 or 2.5mM) followed 
by SDS-PAGE and coomassie staining. Left-most lane had no BS3 indicating the 
monomeric species. Oligomerization state was inferred from reference to a 
molecular weight ladder. (D) In vitro enzymatic IC50 assay using a truncated form 
of PHGDH3-314. Initial reaction rates (Vi) normalized to the DMSO control (Vo) are 
plotted. The IC50 for three independent experiments is given plus or minus SD.  
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Figure 2.28. Disruption of the PHGDH tetramer is not time-dependent. 
PHGDH was preincubated with CBR-5884 (0, 50, 200µM) for 10min to 1.5h prior 
to crosslinking with BS3 (0.25mM or 2.5mM) followed by SDS-PAGE and 
coomassie staining. 
 
 
 
Preliminary structure-activity relationship around the CBR-5884 scaffold 
 
 In order to increase the drug-like nature of CBR-5884 and optimize 
potency, we performed a small structure-activity relationship (SAR) study around 
the CBR-5884 scaffold. We were concerned with the relatively high doses of 
CBR-5884 required for in vitro activity and with the presence of thiophene and 
furan moieties. Both furan and thiophene moieties are susceptible to cytochrome 
P450 (CYP) oxidation forming a 2,3-epoxide that can ablate inhibitory activity and 
result in further metabolism of the compound to potentially toxic products 85. 
Attempts to replace the furan with various benzyl substituents and a single 
chlorothiophene substituent were unsuccessful in that a majority of the resultant 
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derivatives were completely inactive (2-6) or five-fold less active (1) in the 
biochemical PHGDH assay suggesting that modifications of the furan moiety are 
poorly tolerated (Figure 2.29). Modifications of the thiophene core resulted in a 5-
10 fold loss in activity (7-9). Interestingly, removing the thiocyano group or 
substituting it with a cyano group decreased activity approximately 10-fold and 5-
fold, respectively, suggesting the thiocyano group might be essential for activity 
(8, 9). While the acid derivative of the parent molecule was equally active the 
tert-butyl ester was inactive (10, 11).  
 
 
Figure 2.29. Preliminary SAR study around the CBR-5884 scaffold. The 
parent compound CBR-5884 is shown as well as the various derivatives. For 
each compound, the associated IC50 determined via an in vitro PHGDH assay is 
provided. NA: not any, meaning no detectable inhibition.  
 
))!
Discussion:   
 !! We have reported the discovery of a novel PHGDH inhibitor, CBR-5884, 
and shown that it inhibits serine synthesis in cells. Furthermore, CBR-5884 
specifically inhibited the proliferation of melanoma and breast cancer lines with 
high levels of serine synthesis activity with little effect on lines reliant on serine 
import. Thus, CBR-5884 is selective for lines addicted to serine synthesis and 
phenocopies sensitivity to PHGDH knockdown. Finally, a biochemical analysis of 
CBR-5884 revealed that it was a non-competitive inhibitor that showed a time 
dependent onset of inhibition and disrupted the oligomerization state of PHGDH.  
Recent work examining how malignant cells rewire their metabolism to 
support growth and proliferation has revealed a number of clinically interesting 
targets 11,86. Perhaps the most promising is the discovery of gain-of-function 
mutations in the isocitrate dehydrogenase (IDH) enzymes that result in the 
production of the oncometabolite 2-hydroxyglutate 64,87. The findings translated 
into chemical probes that yielded insights into the biology of IDH mutations 70,88 
and led to clinical programs (eg. NCT02481154). The genetic evidence pointing 
to a role for PHGDH in cancer is similarly striking: PHGDH is one of few 
metabolic enzymes genetically deregulated in cancer 63,89. Notably, elevated 
PHGDH expression correlates with clinical aggressiveness and poor prognosis in 
TNBC 45,47 and NSCLC 41. There is a paucity of targeted therapies for these 
cancers and chemotherapies remain mainstay 90,91. Hence, the clinical potential 
of PHGDH inhibitors as targeted agents for TNBC and NSCLC tumors addicted 
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to serine synthesis, as a single agent or in combination with standard of care, is 
an exciting perspective.  
 Beyond the preclinical applications, a PHGDH inhibitor provides a new 
tool to study de novo serine synthesis. For example, it remains unclear why a 
serine biosynthesis enzyme is critical for tumor growth when serine is available in 
the serum 44,45. CBR-5884 provides a valuable tool complementary to genetic 
strategies to study this and other phenomena as small molecules provide greater 
temporal resolution and do not deplete the actual protein. The dynamic nature of 
metabolic flux means that the initial perturbation in flux following PHGDH 
knockdown may resolve to a new steady state before one can interrogate the 
system. With the greater temporal resolution of an inhibitor, these early and 
potentially important events can be studied. Moreover, CBR-5884 has already 
suggested an interesting feature of PHGDH biochemistry, namely that human 
PHGDH could be regulated by transitions between different oligomerization 
states. These findings are reminiscent of pyruvate kinase M2 (PKM2) regulation 
in that both an endogenous metabolite, fructose-1,6-bisphosphate, and 
pharmacological small molecule activators enhance PKM2 activity by stabilizing 
the tetrameric form 92,93. Endogenously, 2-phosphoglycerate (2PG) has been 
reported to activate PHGDH 94. Mechanistically, 2PG could be functioning by 
modulating the PHGDH oligomerization state. Thus, it would be interesting to 
determine whether 2PG modulates the PHGDH oligomerization state or, more 
generally, whether PHGDH activity is subject to such regulation in situ. Finally, it 
is possible that CBR-5884 is a covalent inhibitor of PHGDH. While PHGDH does 
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not rely on an active site cysteine, there are a number of cysteines that could 
potentially perturb enzymatic function were they modified (PDB: 2G76). In an 
attempt to determine whether changes in PHGDH oligomerization state are 
unique to CBR-5884, it would be interesting to determine whether disulfiram 
(CBR-5807), CBR-6936, or sulfhydryl blocking reagents have similar effects.  
The identification of a selective novel small molecule inhibitor of PHGDH 
capable of modulating de novo serine synthesis in PHGDH-dependent cancer 
cells represents a significant step towards the goal of targeting cancer 
metabolism in oncology. However, future in vivo evaluation of the CBR-5884 
chemical series will require medicinal chemistry-based optimization. Indeed, 
CBR-5884 was found to be unstable in mouse plasma (data not shown) and, as 
described above, replacement of the ethyl ester moiety with the corresponding 
negatively charged carboxylic acid resulted in a derivative that retains enzyme 
inhibitory activity but loses activity on cells. Thus, CBR-5884 is more likely to 
serve as a tool compound, and as a starting point for generating more drug-like 
molecules, than an actual drug. Efforts aimed at identifying cell permeable 
plasma-stable derivatives are ongoing. Furthermore, the cell-based potency of 
this series will likely need to be improved to enable in vivo evaluation at exposure 
levels that are not generally toxic. Medicinal chemistry approaches aimed at 
optimizing the potency and ADME properties of CBR-5884 are ongoing. 
Nevertheless, our results provide a proof-of-concept that small molecule 
inhibitors of PHGDH represent a viable new class of anti-cancer drugs.  
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Methods 
 
Cells, transfections, and infections:  
Breast and melanoma lines were passaged in RPMI supplemented with: 
10% FBS, penicillin, streptomycin, normocin (InvivoGen). For lentivirus 
production and infection, Lenti-X 293T cells (Clontech) were transfected at 90% 
confluence with lipofectamine 2000 (Invitrogen) with the indicated pLKO.1 
shRNAs and packaging plasmids pCMV-dR8.2 and pCMV-VSV-G. PHGDH, 
sh1: TRCN0000233029; sh2: TRCN0000221864; nontargeting control, 
shGFP: TRCN0000072181. Viral supernatants were collected after 2 and 3 days. 
Filtered (0.45µm) viral supernatant supplemented with 2µg/ml polybrene was 
added to target cells overnight, and media changed the next morning. Selection 
(2µg/ml puromycin) was initiated the following day for 3 days at which point the 
cells were either harvested for protein or seeded for proliferation assays. Breast 
cell lines were obtained from ATCC and melanoma lines were a gift from Dr. 
Haoqiang Ying (MD Anderson Cancer Center).   
 
Immunoblots: 
 Media was removed, cells were washed with PBS, and proteins were 
isolated directly from intact cells via acid extraction using a 10% TCA solution 
(10mM Tris-HCL pH 8.0, 10% trichloroacetic acid, 25mM NH4OAc, 1mM 
Na2EDTA). Precipitated proteins were harvested and solubilized in a 0.1 M Tris-
HCl, pH 11 solution containing 3% SDS and boiled for 5-10 minutes. Lysate 
protein content was quantified via the BCA method, run on an SDS-PAGE, 
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transferred to a nitrocellulose membrane, blocked (5% BSA), and probed with 
primary antibodies: !PHGDH (Sigma HPA021241, 1/10000, 5% BSA); !Vinculin 
(Sigma V9264, 1/5000, 5% BSA).  
 
Proliferation assays:  
Cells were plated at a low density in 96 or 24 well plates in serine 
containing media. The following day, media was aspirated, cells were washed 
with PBS, and fresh serine replete or serine deplete media containing drug 
(15µM, 30µM) or vehicle (DMSO) was added. Serine replete or deplete media 
was made from serine/ glycine free DMEM (containing pyruvate) that had been 
supplemented with 10% dialyzed FBS and either serine (400µM final, serine 
replete) or PBS (serine deplete). Cells were grown for 3 to 5 days, adding fresh 
drug containing media everyday, before assaying relative cell numbers. For 96 
well plates, relative cell numbers were determined using a Cyquant (Life 
Technologies) assay according to the manufacturer’s instructions. For 24 well 
plates, crystal violet staining was performed as follows: cells were washed with 
PBS, fixed with 10% formalin (10min), washed twice with PBS and stored at 4oC 
in PBS until the completion of the experiment after which PBS was removed and 
cells were stained with 0.1% crystal violet in 20% methanol for 15min. After 
staining, cells were washed thrice with water and air dried overnight. Cell-bound 
crystal violet was solubilized in 10% acetic acid and 595nm absorbance 
measured. Serine/glycine free DMEM was custom ordered from Gibco. 
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Carney serine labeling time course and acute drug treatments with 13C6-
glucose tracing:  
Carney cells were acclimated to growth in MEM (Corning) supplemented 
with 10% dialyzed FBS, penicillin, streptomycin, and normocin (InvivoGen) by 
passaging for 2 weeks (~6 passages). Cells were plated at 9#105 cells per 6cm 
dish a day prior to the experiment. For the serine labeling time course: cells were 
washed with PBS and fresh glucose free MEM supplemented with 13C6-glucose 
(3g/L, Cambridge Isotopes) and 10% dialyzed FBS was added. Cells were then 
incubated at 37oC and harvested, over 9 time points covering a range of 0.12h to 
6h, by quickly washing cells with cold PBS and flash freezing. For acute drug 
inhibition assays: media was replaced with fresh media containing CBR-5884 
(1µM, 15µM, 30µM) or vehicle control (DMSO) for 1h. Media was then aspirated, 
cells were washed with PBS, and fresh glucose free MEM supplemented with 
13C6-glucose (3g/L, Cambridge Isotopes) and 10% dialyzed FBS containing drug 
or DMSO was added. After 2h, cells were quickly washed with cold PBS on ice 
and flash frozen. Polar metabolites were then extracted and analyzed as 
described in the GCMS methods. The seven initial lead PHGDH inhibitors were 
assayed as in the CBR-5884 dose response experiment except that only 30µM 
drug or DMSO control conditions were used. Glucose free MEM was custom 
ordered from Gibco. 
 
Acute toxicity assay:  
Carney cells acclimated to growth in MEM media supplemented with 10% 
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dialyzed FBS, penicillin, streptomycin, and normocin (InvivoGen) were plated in a 
96 well plate at 6,000 cells/well. The next day, cells were treated with CBR-5884 
from 1µM to 40µM for 3h. Drug containing media was then removed, fresh drug-
free media added, and cell viability was determined via a CellTiter-Glo (Promega 
G7572) or Alamar Blue (Invitrogen DAL1025) assay according to the 
manufacturers’ protocol. For Alamar Blue assays, cells were incubated with 
Alamar Blue containing media for 2h at 37°C following removal of drug before 
reading fluorescence.  
 
GCMS metabolite analysis:  
Polar metabolites were extracted with 2ml MeOH/H2O (4:1) for 30min on 
dry ice, scraped, transferred to 2ml tubes, centrifuged (30min, 15000rpm), and 
the supernatants dried under vacuum. Samples were derivatized as previously 
described using methoxyamine hydrochloride and N-Methyl-N-tert-
butyldimethylsilyltrifluoroacetamide (34). Samples were pulse spun to remove 
insoluble matter, the supernatant transferred to inserts set in brown glass vials 
and capped. Analysis was performed on an Agilent 6890 GC instrument. 
Samples were loaded onto a 30m DB-35MS capillary column using helium carrier 
gas and interfaced to an Agilent 5975B MS. Electron impact (EI) ionization was 
set at 70eV. Each sample was injected at 270°C at a flow rate of 1 ml/min. To 
mobilize metabolites, the GC oven temperature was held at 100°C for 3 min and 
increased to 300°C at 3.5°C/min for a total run time of approximately 1h. 1µl of 
each sample was injected in splitless mode. All analyses were operated in full 
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scan mode while recording a mass to charge ratio ($m/z) spectra in the range of 
100-650 m/z. Specific metabolite $m/z analyzed are available upon request. For 
quantification of metabolites, unknown samples were fit to a standard curve of 
known metabolites assessed in the linear range of 0.006-0.33 nmoles on column. 
Standards were run in parallel to samples in order to maintain accuracy of retrofit 
quantitation. Fractional enrichment of 13C in metabolites has been corrected for 
the natural abundance of 13C and 15N using METRAN and in house scripts 
written in Matlab (35, 36). 
 
LC-MS/MS metabolite analysis:   
Polar metabolites were extracted and dried as in the GCMS method. 
Samples were resuspended in 15µl of HPLC grade water. 5µl of each sample 
was injected and analyzed using a 5500 QTRAP triple quadrupole mass 
spectrometer (AB/Sciex) coupled to a Prominence UFLC system (Shimadzu) as 
reported previously 4,95. 
 
PHGDH and PSAT1 purification:  
pET28a PHGDH, pET28a PSAT1, or pNIC28-Bsa4 PHGDH3-314, was 
transformed into BL21 E. coli. A single colony was grown to an OD600 0.7 in 1L of 
Luria broth and protein expression was induced with IPTG (0.5mM). The culture 
was chilled on ice for 30min, cultured for 20h at room temp, pelleted (6000g, 
20min), and flash frozen. Pellets were resuspended in 60ml of lysis buffer (50mM 
Tris pH 8.5, 10mM MgCl2, 300mM NaCl, 10% glycerol, 5mM imidazole), 
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sonicated and cell debris pelleted by centrifugation (20,000g, 30min). The 
supernatant was collected and 2ml of Ni-agarose beads (Qiagen), pre-washed 
twice with wash buffer (50mM Tris pH 8.5, 10mM MgCl2, 300mM NaCl, 10% 
glycerol, 30mM imidazole), and 60µl of 2-mercaptoethanol were added. Beads 
and lysate were incubated for 3h on a rocker at 4°C. Beads were batch-washed 4 
times with wash buffer and transferred to a column. Bound proteins were eluted 
(elution buffer: 50mM Tris pH 8.5, 10mM MgCl2, 250mM NaCl, 10% glycerol, 
250mM imidazole) collecting 1ml fractions. Fraction protein content was 
measured via a Bradford assay. The most concentrated fractions were pooled 
and dialyzed overnight into 2L of dialysis buffer (50mM Tris pH 8.5, 10mM MgCl2, 
250mM NaCl, 20% glycerol, 0.15% 2-mercaptoethanol). The next morning, 
dialysis buffer was changed and dialysis continued for 4h. Protein purity was 
assessed via SDS-PAGE and coomassie staining.  
 
IDH1 purification:  
IDH1 gene was PCR amplified from SC322129 (IDH1 (NM_005896) 
Human cDNA) from Origene. The cDNA sequence was cloned into a pVB-CBD 
vector by inserting the IDH1 gene downstream of OmpA and CBD (cellulose 
binding domain). BL21-Gold (DE3) cells (Agilent) were transformed with the pVB-
CBD-IDH1 plasmid and single colonies were generated. Protein expression was 
performed under IPTG (1mM) induction at 25°C for 24h. The supernatant 
containing the IDH1 protein was separated by centrifugation. The IDH1-CBD was 
captured on a Macroporous Bead Cellulose MT100 column (Iontosorb). TEV 
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protease (Sigma-Aldrich) digestion was performed at 37°C for 1 hour. Size 
exclusion FPLC was performed using a Superdex 200 10/300 GL (GE Health 
Care Life Sciences) column. Purified protein purity was more than 95% as 
determined by SDS-PAGE.  
 
PHGDH assays:  
PHGDH activity was measured in 96-well plates (100µL/well) at 28°C by 
monitoring NADH fluorescence (Ex340nM/ Em460nM) over time with a FLUOstar 
Omega (BMG labtech). PSAT1 was included to prevent product inhibition of 
PHGDH. Assays were performed in PHGDH assay buffer (50mM Tris pH 8.5 and 
1mM EDTA). Substrates and enzyme concentrations were: 3-phosphoglycerate 
240µM; NAD+ 120µM; glutamate 30mM; 5.7ng/µl for full length PHGDH or 
240ng/µl for PHGDH3-314; PSAT1 80ng/µl except for Ki measurements where one 
of the PHGDH substrates was held constant at 3mM while the other substrate 
was titrated from 2mM to 8µM for NAD+ or 1mM to 0.15µM for 3PG. An NADH 
standard curve in PHGDH assay buffer was included to quantify fluorescent 
signal. For IC50 assays, a 2-fold serial dilution of drug ranging from 160µM to 
0.15µM was preincubated with enzyme for 30min before initiating the enzyme 
reaction with substrate mix. For time dependent IC50 assays, drug preincubation 
time was 4h, 1h, or 30min. For Ki measurements, drug  (0, 15µM, 30µM, 80µM) 
and enzyme were preincubated for 30min. Initial rate plots were fit using Prism. 
Chemicals were purchased from Sigma. 
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LDH and MDH1 assays:   
Enzyme activities were assayed using kits (LDH: Sigma MAK06; MDH1: 
Sigma MAK196-1KT) according to the manufacturer’s instructions with 
commercially available recombinant enzyme (LDH: Sigma 59747; MDH1: Sigma 
SRP6103). Drug, titrated as for the PHGDH IC50 assays, and enzyme were pre-
incubated for 30min prior to initiating reaction with substrate.  
 
Cross-linking assays:  
PHGDH (1.5µg) or LDH (2.2µg, Sigma 59747) were incubated with CBR-
5884 (50µM, 200µM, 400µM) or vehicle control (DMSO) in 25mM HEPES, pH 
7.3, and 1mM NAD+ in 18µL total volume for 30min.  BS3 (Pierce, PI-21585) 
cross-linker dissolved in PBS was added to a final concentration 0, 0.25mM, or 
2.5mM and incubated for 30min on a rocker. The reaction was then quenched for 
15min by adding 1M Tris pH 7.5 to a final concentration of 27mM. Cross-linked 
proteins were mixed with sample buffer, boiled for 5min, and run on SDS-PAGE. 
Gels were stained with colloidal coomassie stain (Bio-Rad 161-0803) for 24h and 
destained according to the manufacturer’s instructions.  
 
Primary PHGDH screen:  
800,000 compounds were screened at a single dose (13.3µM) in 1536-
plate format. Bromopyruvate (0.5mM) was used as inhibitor control. Assay set 
up: 2µL of assay buffer was added to each well of a 1536 well plate. Compounds 
were transferred and 2µL of reaction mixture 2 was added followed by a 3-min 
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incubation. Reactions were initiated by adding 2µL of reaction mixture 1. Plates 
were incubated (30min at 37°C) before fluorescence quantification (550/590nm; 
Ex/Em) using an Envision plate reader. Reaction mixture 1: 3-phosphoglycerate 
(0.25 mM), resazurin (0.1 mM), NAD+ (8.3 mM), glutamic acid (30 mM), Tris-HCl 
pH 8.0 (30 mM), 0.6mM EDTA. Reaction mixture 2: PSAT1 (0.02 ug/uL), PHGDH 
(0.005 ug/uL), and diaphorase (0.001 U/uL) diluted in Tris-HCl pH 8.0 (30 mM) 
and EDTA (0.6mM) buffer. Assay buffer Tris-HCl pH 8.0 (30 mM) and EDTA 
(0.6mM). 
 
Diaphorase counterscreen:  
All 800,000 compounds were screened against diaphorase (Worthington 
Biochemical Corporation) as in the primary screen but drug and enzyme were 
incubated for 20min at 25°C before initiating the reaction. Modified reaction 
mixtures were as follows. Mixture 1: resazurin (0.1 mM), NADPH (0.1 mM), buffer 
(30 mM Tris-HCl, 0.6 mM EDTA pH 8.0). Mixture 2: diaphorase (0.0002 U/uL), 
buffer (30 mM Tris-HCl, 0.6 mM EDTA pH 8.0). 
 
Screening hit selection criteria, confirmation, and selectivity profiling:  
 Results were analyzed using Genedata Screener software. Compounds 
with a robust Z-score < -3 in the PHGDH screening assay and robust Z-score > -
2 in the diaphorase counter screen were selected as hits. Hit confirmation was 
done in triplicate (13.3µM) in 1536-plate format as described above. In order to 
assess selectivity of confirmed hits, hits were tested in 1536-plate format in an 8-
*+!
point dose-response experiment (2-fold serial dilution) against a panel of 
dehydrogenases including: PHGDH, isocitrate dehydrogenase (IDH1), malate 
dehydrogenase (MDH1), and 3!-hydroxysteroid dehydrogenase (3!-HSD). 
PHGDH assay: performed as in the primary screen. IDH1 assay: 2%L of assay 
buffer was added to each well. Compounds were transferred and 2%L of reaction 
mixture 2 was added followed by a 3-min incubation. Reactions were started by 
the addition of 2%L of reaction mixture 1. Plate was incubated for 45 min at 37°C 
before fluorescence quantification. MDH1 assay: 2%L of assay buffer was added 
to each well. Compounds were transferred and 2%L of reaction mixture 4 was 
added followed by a 3-min incubation. Reactions were started by the addition of 
2%L of reaction mixture 3. Plate was incubated for 2.5h at 37°C before 
fluorescence quantification. 3!-HSD assay: 2%L of assay buffer was added to 
each well. Compounds were transferred and 2uL of reaction mixture 6 was 
added followed by a 3-min incubation. Reactions were started by the addition of 
2%L of reaction mixture 5. Plate was incubated for 30 min at 37°C before 
fluorescence quantification. In all cases fluorescence (550/590nm; Ex/Em) was 
quantified with an Envision plate reader and IC50 values were obtained using 
Genedata Screener software. Compounds that were not at least 4-fold selective 
for PHGDH were eliminated and the seven most potent PHGDH inhibitors were 
selected for further cell-based work. Reaction mixture 1: isocitrate (0.36 mM), 
resazurin (0.1 mM), NADP+ (0.033 mM), MnCl2 (1 mM), buffer (30 mM Tris-HCl, 
0.6 mM EDTA pH 8.0). Reaction mixture 2: IDH1 (0.25 %g/%L; purified in house), 
and diaphorase (0.005 U/%L) diluted in buffer (30 mM Tris-HCl, 0.6 mM EDTA pH 
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8.0). Reaction mixture 3: L-malic acid (2 mM), resazurin (0.1 mM), NAD+ (0.5 
mM), buffer (30 mM Tris-HCl, 0.6 mM EDTA pH 8.0). Reaction mixture 4: porcine 
MDH1 (Sigma M2634, 0.00025 %g/%L), and diaphorase (0.005 U/%L), buffer (30 
mM Tris-HCl, 0.6 mM EDTA, pH 8.0). Reaction mixture 5: cholic acid (0.05 mM), 
resazurin (0.1 mM), NAD+ (0.007 mM), buffer (20 mM sodium pyrophosphate pH 
9.0, 4 %g/mL BSA). Reaction mixture 6: 3a-HSD (from Sigma; 0.025 %g/%L), and 
diaphorase (0.005 U/%L), buffer (20 mM sodium pyrophosphate pH 9.0, 4 %g/mL 
BSA). Chemicals were purchased from sigma and diaphorase from Worthington 
Biochemical Corporation 
 
Chemical syntheses: 
 
Materials:  
2-amino-4-methyl-3-cyanato-5-thiophenecarboxylate ethyl ester was 
obtained from Life Chemicals.  Cyanoacetic acid was obtained from AK 
Scientific.  All remaining reagents and solvents were obtained from Sigma-
Aldrich.  All reagents were used as received without further purification.  
 
Ethyl 5-(furan-2-carboxamido)-3-methyl-4-thiocyanatothiophene-2-
carboxylate:  
86.3 mg 2-amino-4-methyl-3-cyanato-5-thiophenecarboxylate ethyl ester 
(357 %mol, 1 eq.) was suspended in 1 mL DCM with a magnetic stirbar (Figure 
2.30). 86.5%L of pyridine (1070 %mol, 3 eq.) was added to the mixture, followed 
*-!
by drop-wise addition of 35.3 %L 2-furoyl chloride (357 %mol, 1 eq.). After 1 hour 
the reaction mixture was purified directly by normal-phase silica gel 
chromatography.  Collected fractions were dried in vacuo to obtain 87.2 mg ethyl 
5-(furan-2-carboxamido)-3-methyl-4-thiocyanatothiophene-2-carboxylate as a 
white solid, 73% yield.  1H NMR (400 MHz CDCl3) & 9.36 (s, 1H), 7.67 (dd, J = 
0.8, 1.7 Hz, 1H), 7.41 (dd, J = 0.8, 3.6 Hz, 1H), 6.67 (dd, J = 1.7, 3.6 Hz, 1H), 
4.36 (q, J = 7.1 Hz, 2H), 1.40 (t, J = 7.1 Hz, 3H) ppm.  LC-MS (M+H)+ = 337.09, 
(M-CN)+ = 310.09. 
 
 
 
Figure 2.30. Synthesis of ethyl 5-(furan-2-carboxamido)-3-methyl-4-
thiocyanatothiophene-2-carboxylate. The synthetic scheme to for CBR-5884 is 
depicted. 
 
 
Tert-butyl 4-cyano-3-methylbut-3-enoate:  
Adapted from literature procedure (39).  5.00 g (36.1 mmol, 1 eq.) tert-
butyl acetoacetate, 2.69 g (31.6 1 eq.) cyanoacetic acid, and 488 mg (6.33 mmol, 
0.2 eq.) ammonium acetate were added to a solution of 0.9 mL acetic acid and 
9.0 mL benzene (Figure 2.31).  The reaction mixture was refluxed in a Dean-
Stark trap for 24 hours.  After cooling to room temperature, the reaction mixture 
was washed with saturated sodium bicarbonate, brine, then dried with sodium 
sulfate and condensed in vacuo. The crude product was vacuum-distilled at 65°C 
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to obtain 1.28g tert-butyl 4-cyano-3-methylbut-3-enoate as a mixture of E/Z 
isomers, 23% yield, clear oil.  1H NMR (400 MHz CDCl3) & 5.30 (m, 2H), 3.36 (d, 
J = 1.5 Hz, 1H), 3.11 (d, J = 1.1 Hz, 1H), 2.15 (d, J = 1.1 Hz, 1H), 2.02 (d, J = 1.5 
Hz, 1H), 1.48 (m, 18H) ppm. 
 
 
 
Figure 2.31. Synthetic scheme for 5-(furan-2-carboxamido)-3-methyl-4-
thiocyanatothiophene-2-carboxylic acid. The synthetic scheme to obtain the 
acid derivative of CBR-5884 is provided.  
 
 
Tert-butyl 5-amino-3-methylthiophene-2-carboxylate:  
Adapted from literature procedure (39).  1.28 g (7.09 mmol, 1 eq.) tert-
butyl 4-cyano-3-methylbut-3-enoate and 227 mg (7.09 mmol, 1 eq.) sulfur flakes 
were suspended in 5.5 mL ethanol.  806 %L (7.80 mmol, 1.1 eq.) diethylamine 
was added drop-wise and the mixture was stirred for 4 hours, forming a dark 
orange/red solution (Figure 2.31).  Reaction mixture was dried in vacuo and 
purified by flash chromatography.  After drying collected fractions in vacuo, 814 
mg tert-butyl 5-amino-3-methylthiophene-2-carboxylate was obtained as a 
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yellow-orange oil, 54% yield.  1H NMR (400 MHz CDCl3) & 5.99 (s, 1H), 4.01 (br. 
s, 2H), 2.40 (s, 3H), 1.552 (s, 9H) ppm. 
 
Tert-butyl 5-amino-3-methyl-4-thiocyanatothiophene-2-carboxylate:  
Adapted from literature procedure (40).  100 mg (0.469 mmol, 1 eq.) tert-
butyl 5-amino-3-methylthiophene-2-carboxylate and 71.4 mg (0.938 mmol, 2 eq.) 
ammonium thiocyanate were dissolved in 0.5 mL methanol and cooled with an 
ice bath (Figure 2.31).  A solution of 14.9 %L (0.291, 0.62 eq.) bromine in 
methanol was added drop-wise to the reaction mixture.  The mixture was stirred 
on ice for 10 minutes; then the ice bath was removed and the mixture stirred for 
another hour while warming to room temperature.  The reaction mixture was then 
dried in vacuo and purified by flash chromatography.  The collected fractions 
were dried in vacuo to afford 32.0 mg tert-butyl 5-amino-3-methyl-4-
thiocyanatothiophene-2-carboxylate as a white solid.  1H NMR (400 MHz CDCl3) 
& 5.05 (br. s, 1H), 2.59 (2, 3H), 1.57 (s, 9H) ppm. 
 
Tert-butyl 5-(furan-2-carboxamido)-3-methyl-4-thiocyanatothiophene-2-
carboxylate:  
Prepared analogously as ethyl 5-(furan-2-carboxamido)-3-methyl-4-
thiocyanatothiophene-2-carboxylate. From 32.0 mg (0.119 mmol) tert-butyl 5-
amino-3-methyl-4-thiocyanatothiophene-2-carboxylate as starting material, 19.8 
mg tert-butyl 5-(furan-2-carboxamido)-3-methyl-4-thiocyanatothiophene-2-
carboxylate was obtained as a white solid, 46% yield (Figure 2.31). 1H NMR (400 
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MHz CDCl3) & 9.35 (s 1H), 7.68 (dd, J = 0.8, 1.7 Hz, 1H), 7.42 (dd, J = 0.8, 3.6 
Hz, 1H), 6.68 (dd, J = 1.8, 3.6 Hz, 1H), 2.72 (s, 3H), 1.60 (s, 9H) ppm. 
 
5-(furan-2-carboxamido)-3-methyl-4-thiocyanatothiophene-2-carboxylic 
acid:  
0.25 mL trifluoroacetic acid was added slowly to a solution of 5.3 mg (13.7 
%mol) tert-butyl 5-(furan-2-carboxamido)-3-methyl-4-thiocyanatothiophene-2-
carboxylate in 0.25 mL dichloromethane in an ice bath and stirred for 30 minutes, 
allowing the mixture to warm to room temperature over time (Figure 2.31).  The 
reaction mixture was dried in vacuo with minimal heating applied (no greater than 
30°C). The dried product was sonicated in diethyl ether to dissolve remaining 
starting material, centrifuged briefly to precipitate the product, then decanted to 
remove starting material in the ether layer. This ether treatment was repeated 
two more times.  After drying the remaining solid in vacuo, 1.6 mg 5-(furan-2-
carboxamido)-3-methyl-4-thiocyanatothiophene-2-carboxylic acid was obtained 
as a white solid, 38% yield.  1H NMR (400 MHz CDCl3) & 7.89 (dd, J = 0.8, 1.8 
Hz, 1H), 7.46 (dd, J = 0.8, 3.6 Hz, 1H), 6.75 (dd, J = 1.8, 3.6 Hz, 1H), 2.71 (s, 
3H) ppm. LC-MS (M+H)+ = 309.0, (M-OH)+ = 291.0, (M-CN)+ = 282.0. 
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Chapter 3: Unresolved Questions, Discussion, and Future Directions 
 
 The work presented in this thesis has uncovered a new small molecule 
inhibitor of PHGDH. CBR-5884 will be a useful probe to further study the 
fundamental biology of serine synthesis both in cancer and non-transformed cells. 
Furthermore, CBR-5884 provides starting chemical matter from which more 
potent inhibitors of PHGDH can be developed.  
In chapter 2, we described an in vitro enzymatic assay for PHGDH 
amenable to high throughput screening and its use to screen a library of 800,000 
drug-like compounds for inhibitors of PHGDH. Following confirmation and 
counter screening, we were able to identify 408 bona fide PHGDH inhibitors. We 
triaged the commercially available subset of hits based on a combination of cell 
based and biochemical enzymatic assays. Thus, we were able to identify one 
compound, CBR-5884, that was selective for PHGDH in a panel of metabolic 
dehydrogenases and inhibited serine synthesis in cancer cells. Importantly, CBR-
5884 was able to selectively inhibit the proliferation of breast cancer and 
melanoma cell-lines that over-express PHGDH while having minimal effects on 
lines that rely on import of extracellular serine. These results phenocopied those 
obtained with PHGDH knockdown in breast and melanoma cell lines, which is 
consistent with an on-target effect of CBR-5884. Biochemical characterization of 
CBR-5884 revealed that it was a non-competitive inhibitor that showed a time 
dependent onset of inhibition and disrupted the oligomerization state of PHGDH. 
Overall, the results suggest that targeting PHGDH in cancers addicted to serine 
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synthesis may be a promising therapeutic strategy. Nevertheless, there are some 
important limitations to CBR-5884 and further work is needed.  
Relatively high concentrations of CBR-5884 were needed to inhibit 
PHGDH overexpressing cancer cell proliferation and the inhibition of serine 
labeling was relatively mild (~30%) at the maximal CBR-5884 dose used (30µM). 
Although we tried to investigate and rule out potential off-target effects, given the 
high concentrations of CBR-5884, it is possible that part of the anti-proliferative 
activity observed results from off-target effects. Using metabolomics to compare 
metabolic changes following drug treatment and PHGDH knockdown, we 
identified glycerol-3-phosphate as a metabolite uniquely perturbed following 
CBR-5884 treatment. Thus, we are currently investigating whether glycerol-3-
phosphate dehydrogenase is inhibited by CBR-5884.  
An additional limitation to CBR-5884 is that it is unstable in mouse plasma 
(data not shown) and that the acid derivative is unable to inhibit cancer cell 
proliferation presumably because it cannot cross the plasma membrane. The 
poor pharmacokinetic properties of CBR-5884 will make it difficult to study the 
effect of PHGDH inhibition in murine cancer models. However, both the limited 
potency and poor pharmacokinetic properties could be ameliorated via medicinal 
chemistry efforts. To this end we are continuing to expand the SAR study around 
the CBR-5884 scaffold. Finally, an additional potential caveat is that CBR-5884 
may well be a covalent inhibitor of PHGDH. A covalent inhibition mechanism 
would be consistent with the noncompetitive mode of inhibition, the importance of 
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the thiocyano group in the SAR study, and the time dependent inhibition 
observed.  
We speculated that the thiocyano group could enable CBR-5884 to form 
an adduct with PHGDH cysteine sulfhydryl groups. In order to evaluate this 
possibility, the tert-butyl derivative of CBR-5884 (11) was incubated with 5mM 
glutathione (1:1 molar ratio) and analyzed by LCMS. Following overnight 
incubation, approximately 80% of compound 11 had been converted to a more 
polar compound with mass attributable to the glutathione adduct with loss of 
cyanide (Supplementary Figure 3.1). To confirm that the species was indeed the 
predicted adduct, an excess of dithiothreitol was added. This resulted in near 
complete recovery of a compound consistent with the free thiol by mass 
spectrometry (Supplementary Figure 3.1). These results suggest that CBR-5884 
might be covalently reacting with PHGDH cysteine sulfhydryl groups and that 
CBR-5884 may be inactivated by glutathione conjugation in cells. It should be 
noted, however, that the rate of adduct formation is likely to be greatly 
overestimated in the above assay compared to the intracellular process given 
that the reaction is bimolecular and both compound 11 and glutathione were 
used at high concentrations (5mM). 
In order to further investigate the potential covalent mechanism of 
inhibition, we examined the crystal structure of the truncated protein, PHGDH3-314 
(PDB: 2G76). Although there are no cysteine residues directly within the active 
site that can directly account for loss of PHGDH activity, there are a number of 
cysteines (C109, C232, C279, C293) that could potentially perturb enzymatic 
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function were they modified given their close proximity to the active site (Figure 
3.1). PHGDH has been reported to rely on histidine and arginine residues for 
catalysis 96,97. The histidine residue serves as a catalytic base to deprotonate the 
3-PG hydroxyl group and the arginine residue coordinates the 3-PG carboxylic 
acid (Figure 3.1). Modification of C279 by CBR-5884 could potentially displace 
the catalytic histidine residue (H281) thereby inhibiting catalysis. Similarly, C232 
modification could perturb R234 coordination of 3-PG. Phosphorylation of 
PHGDH threonine 77 by PKC zeta has been suggested to inhibit PHGDH 
activity, supporting the notion that modification of the cysteine residues could 
perturb enzymatic function (Figure 3.1) 98.  
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Figure 3.1: Structure of the PHGDH3-314 active site. PHGDH catalyzes the 
oxidation of the 3-PG hydroxyl group to a ketone. The NAD+ cofactor and 3-PG 
substrate analog malate (MLT) are shown in purple. PHGDH residues discussed 
are shown in grey. H281 catalytic base that abstracts the hydroxyl proton 
enabling ketone formation with a hydride transfer to NAD+. R234 coordinates the 
3-PG carboxylic acid. Cysteine residues that could potentially be modified by 
CBR-5887 to inhibit PHGDH activity are shown. The putative AGC kinase site, 
T77 putative, that is phosphorylated in vitro by PKC zeta inhibiting PHGDH 
activity is shown 98. PHGDH3-314 structure, PDB: 2G76. 
 
 
Covalent modification of the cysteines proximal to the PHGDH active site 
could account for the time dependent inhibition of PHGDH and for why both the 
full length and truncated protein are inhibited. However, it would not account for 
the disruption of the tetrameric form of the full-length protein. Inspection of the 
PHGDH primary amino acid sequence indicates that there are cysteine residues 
in the full-length protein not present in the truncated protein. Were these cysteine 
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residues located at critical regions of the dimer-dimer interfaces, they could 
perhaps account for disruption of the tetramer.  
In order to determine whether CBR-5887 is functioning though a covalent 
mechanism targeting cysteine residues, three parallel approaches are being 
followed. First, site directed mutagenesis is being pursued to determine whether 
point mutation of any of the cysteine residues can rescue from CBR-5884 
inhibition and/or rescue disruption of the tetrameric form of PHGDH. Second, we 
are attempting to map the cysteine residues potentially modified by CBR-5884 
via an LCMS based proteomic approach. Third, we are investigating whether 
thiol blocking reagents such as iodoacetamide and N-ethylmaleimide (NEM) can 
also inhibit PHGDH and disrupt the PHGDH oligomerization state.  
It is important to determine whether CBR-5884 is a covalent modifier 
because this will determine how best to optimize the molecule. Covalent 
modifiers are traditionally undesirable in drug discovery because of potential 
toxicity issues (eg. hapten formation). Moreover, covalent inactivation is often 
considered a non-drug like mechanism of action in that the drug may be 
promiscuous and react with other proteins using the same covalent mechanism 
99. Nevertheless, covalent drugs are widely and safely used in the clinic (eg. 
beta-lactam antibiotics like penicillin) and recently there has been renewed 
interest in developing covalent kinase inhibitors in oncology 100. In order to 
optimize selectivity, the current covalent drug design strategy focuses on 
developing probes that form a strong initial non-covalent complex with the 
enzyme, with the covalent warhead only reacting after the probe is bound and 
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with a specific residue that has the right geometric orientation with respect to the 
bound drug 99,100.  
 Given the design strategy of covalent probes discussed, one potential 
concern is that the CBR-5884 thiocyano group is non-specific in its mechanism of 
covalent inhibition. The dehydrogenase enzyme panel used to profile CBR-5884 
selectivity (Table 2) may have lacked enzymes that contain an active site or 
otherwise important cysteine susceptible to CBR-5884 modification and may 
therefore have failed to identify the promiscuity of CBR-5884. In order to assess 
whether the presence of cysteine residues in close proximity to the active site 
was a unique feature of PHGDH, we examined the crystal structure of LDH 
(PDB: 9LDT). Analogous to PHGDH, the LDH structure revealed a catalytic 
histidine residue and arginine residues that coordinate the substrate carboxylic 
acid 101-103. Importantly, as with PHGDH, LDH cysteine residues (C35 & C165) 
were found in close proximity to the active site. Given that CBR-5884 did not 
inhibit LDH it suggests that CBR-5884 might harbor some specificity for PHGDH. 
Moreover, given that the CBR-5884 derivative in which the thiocyano group is 
replaced with a cyano group (9) still inhibits PHGDH, it would suggest that CBR-
5884 harbors some specificity for PHGDH, at least to the extent that formation of 
a relatively weak non-covalent complex is indicative of specificity. 
In order to further validate that the mechanism of CBR-5884 inhibition is 
specific despite its cysteine targeting mechanism, we will profile the activity of 
CBR-5884 against other enzymes, such as GAPDH, that are known to rely on a 
catalytic cysteine residue for activity 33. It should be noted, however, that 
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metabolic profiling of cells treated with CBR-5884 did not reveal perturbations of 
glycolytic flux downstream of GAPDH (Figure 2.16) as would be anticipated were 
the GAPDH catalytic cysteine targeted 6. From a medicinal chemistry 
perspective, given that compound 9 only binds weakly to PHGDH, it would be 
important to improve the binding affinity of the non-covalent CBR-5884 scaffold 
and investigate whether the thiocyano moiety can be replaced with other 
covalent warheads such as an acrylamide moiety. For covalent kinase inhibitors, 
covalent warheads are typically only introduced after submicromolar non-
covalent binding affinity has been achieved 104. While CBR-5884 treatment only 
induces modest inhibition of serine labeling in cells, improved non-covalent 
binding of the CBR-5884 scaffold and modifications of the covalent warhead may 
lead to more selective and potent inhibition of PHGDH in cells. 
  Given that in pursing the results from the PHGDH inhibitor screen we 
focused on hits that were commercially available, we were only able to pursue 45 
of the 408 PHGDH inhibitors identified. Thus, we are planning to synthesize 
some of the top compounds from the hit list in order to evaluate them in the cell 
and biochemical based assays developed. Top hits will be selected for 
resynthesis based on observed potency, selectivity, drug-like properties, and 
number of occurrences of the identified scaffold in the hit list. Using this approach 
we may be able to identify more potent and drug like scaffolds than that of CBR-
5884.  
 Discovering that CBR-5884 induced dissociation of the tetrameric form of 
PHGDH to favor the dimeric form led us to ponder whether PHGDH activity could 
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be regulated by transitions between the tetrameric and dimeric forms in cells and 
whether disruption of the PHGDH tetramer was part of the inhibitory mechanism 
of CBR-5884. Precedence for metabolic enzymes being regulated in such a 
manner has been established for pyruvate kinase M2: an endogenous metabolite 
(fructose-1,6-bisphosphate), and pharmacological small molecule activators 
enhance PKM2 activity by stabilizing the tetrameric form over the less active 
dimeric form 92,93. PHGDH is a tetramer formed from a dimer of dimers. The 
primary dimer is formed from interactions between the nucleotide binding domain 
of two monomers; tetramers then form by dimers interacting through their C-
terminal domains (CTD). In E.coli, PHGDH is allosterically inhibited by serine via 
a Vmax effect and the mechanism of inhibition involves serine binding to the 
interface of two CTDs 105. While serine based feedback inhibition is not 
conserved in vertebrates, these observations suggest that it is possible that 
human PHGDH may also be regulated via modulation of the CTD and that this 
could lead to the disruption of the tetramer 78. Consistent with the notion that 
disruption of the tetrameric form of PHGDH could be inhibitory, we noted that 
truncated PHGDH3-314, which lacks the CTD and is therefore a constitutive dimer, 
had a specific activity ~5-fold lower than that of the full-length protein 
(Supplementary Figure 3.2). Furthermore, we noted that a significant fraction of 
patients with inherited disorders in serine synthesis are known to have missense 
mutations in the PHGDH CTD 106. The mechanism by which CTD mutations 
disrupt PHGDH activity is still controversial but decreases in Vmax have been 
reported 106-108. These observations are consistent with a model in which PHDGH 
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activity may be regulated by transitions between dimer and tetrameric states. 
Having purified the various PHGDH CTD point mutants we are currently 
investigating whether their kinetic parameters and tetramer to dimer ratios differ 
from the wildtype protein. Preliminary experiments suggest that the mutants are 
somewhat less active and favor the dimeric form (data not shown), but further 
work is needed to validate our model. Finally, we also plan to investigate whether 
the endogenous activator of PHGDH, 2-phospohglycerate, could be functioning 
by modulating the PHGDH oligomerization state 94.  
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Appendix A: Identification of a Small Molecule Inhibitor of 3-
Phosphoglycerate Dehydrogenase to Target Serine Biosynthesis in Cancer. 
 
A copy of the manuscript accepted for publication in the Proceedings of the 
National Academy of Sciences is provided below.  
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Abstract 
 
Cancer cells reprogram their metabolism to promote growth and 
proliferation. The genetic evidence pointing to the importance of the amino acid 
serine in tumorigenesis is striking. The gene encoding the enzyme 3-
phosphoglycerate dehydrogenase (PHGDH), which catalyzes the first committed 
step of serine biosynthesis, is overexpressed in tumors and cancer cell lines via 
focal amplification and NRF2-mediated upregulation. PHGDH overexpressing 
cells are exquisitely sensitive to genetic ablation of the pathway. Here, we report 
the discovery of a novel and selective small molecule inhibitor of PHGDH, CBR-
5884, identified by screening a library of 800,000 drug-like compounds. CBR-
5884 inhibited de novo serine synthesis in cancer cells and was selectively toxic 
to cancer cell lines with high serine biosynthetic activity. Biochemical 
characterization of the inhibitor revealed that it was a non-competitive inhibitor 
that showed a time dependent onset of inhibition and disrupted the 
oligomerization state of PHGDH. The identification of a small molecule inhibitor 
of PHGDH not only enables thorough preclinical evaluation of PHGDH as a 
target in cancers, but also provides a tool with which to study serine metabolism.  
 
Significance statement  
 
Serine supports a number of anabolic processes including protein, lipid, 
and nucleic acid synthesis. Cells can either import serine or synthesize it de 
,,!
novo. Recently, overexpression of PHGDH, the gene encoding the first 
committed step of serine synthesis, via focal amplification and NRF2-mediated 
upregulation, has been identified in human cancers. Cancer cell lines that 
overexpress PHGDH via amplification, or transcriptional upregulation, are 
uniquely sensitive to PHGDH knockdown while lines that express little PHGDH 
are insensitive suggesting that PHGDH may be a clinically interesting target. 
Here, we report a novel and specific small molecule inhibitor of PHGDH, which 
enables preclinical evaluation of PHGDH as a target in cancer and provides a 
tool to study the biology of de novo serine synthesis. 
 
Introduction 
 
Serine is required for a plethora of anabolic processes. Serine is an 
abundant component of proteins and is required for the synthesis of lipids 
including sphingolipids and phosphatidylserine, a major component of cellular 
membranes 1-3. Alternatively, serine hydroxymethyltransferases (SHMTs) convert 
serine to glycine concomitantly charging the folate pool with “one-carbon” units 
4,5. Both glycine and folate one-carbon units are used to make nucleotides. Thus, 
serine serves numerous critically important roles in cellular metabolism. 
At the cellular level, serine can be imported from the extracellular space 
via amino acid transporters 6,7. Alternatively, serine can be synthesized from 
glucose via the phosphoserine pathway 8. De novo synthesis proceeds from the 
glycolytic intermediate 3-phosphoglycerate (3-PG) via three sequential enzymatic 
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reactions (Figure A.1), the first of which is catalyzed by the NAD+ dependent 
enzyme 3-phosphoglycerate dehydrogenase (PHGDH) 9. For decades, it has 
been known that cancer cells have enhanced serine synthesis, which contributes 
to nucleotide synthesis 10,11. Recently, focal amplifications of the gene encoding 
PHGDH have been reported, particularly in breast cancers and melanomas 12-14. 
Additionally, KEAP1 and NRF2 mutant non-small cell lung cancers (NSCLC) 
overexpress PHGDH 15. Proliferation of PHGDH amplified cancer cell lines, and 
other lines that overexpress PHGDH without amplification, is inhibited by PHGDH 
knockdown. In contrast, lines that express little PHGDH are resistant to shRNA 
mediated ablation of the pathway presumably because serine import suffices 
13,14. A detailed mechanistic understanding of why some cancer cells are 
addicted to serine synthesis despite the availability of extracellular serine for 
import remains unclear. Interestingly, in triple negative breast cancer (TNBC) and 
NSCLC, PHGDH amplification and overexpression are associated with more 
aggressive disease 13-16. Thus, PHGDH inhibitors as a targeted therapy for these 
tumor types represents an exciting clinical opportunity.  
 The studies herein detail our efforts in identifying small molecule inhibitors 
of PHGDH. We reasoned that a PHGDH inhibitor would have the benefits of not 
only providing a tool compound with which to study the biology of serine 
synthesis, but also enable thorough preclinical evaluation of PHGDH as a target 
in cancers. We screened a library of 800,000 small molecules using an in vitro 
PHGDH assay. A cell-based assay for serine synthesis was used to identify a 
lead, CBR-5884, that was active in cells. CBR-5884 selectively inhibited the 
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proliferation of melanoma and breast cancer lines that have a high propensity for 
serine synthesis, but had no effect on lines that rely on extra-cellular serine 
uptake. Mechanistically, CBR-5884 was found to be a noncompetitive inhibitor, 
showed a time dependent onset of inhibition, and disrupted the oligomerization 
state of PHGDH.  
 
Results 
 
Screening for small molecule inhibitors of PHGDH.  
 
An in vitro enzymatic assay for PHGDH activity amenable to high-
throughput screening (HTS) was developed by coupling the production of NADH, 
upon 3PG oxidation, to the reduction of resazurin to resorufin using diaphorase 
as the coupling enzyme (Figure A.1). Thus, resorufin fluorescence served as a 
proxy for PHGDH activity. The assay was miniaturized to 1536 well format with a 
Z-factor of >0.75 indicating a high quality assay 17. A library of 800,000 small 
molecules was screened in single point format at 13µM (Figure A.1). Setting a 
threshold Z score of -3, corresponding to at least 50% PHGDH inhibition, gave a 
0.5% hit rate yielding 3,906 hits. Putative hits were re-assayed in triplicate and 
counter screened against diaphorase to rule out false positives targeting 
diaphorase. The counter screen eliminated 3,498 compounds giving 408 PHGDH 
inhibitors (Figure A.1).  
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Figure A.1. Screening for inhibitors of PHGDH. (A) Serine synthesis from 
glucose via the phosphoserine pathway: phosphoglycerate dehydrogenase 
(PHGDH) oxidizes the glycolytic intermediate 3-phosphoglycerate (3-PG) to 3-
phosphohydroxypyruvate (p-Pyr) using NAD+; phosphoserine amino transferase 
(PSAT1) transaminates p-Pyr to phosphoserine (p-Ser) using glutamate as a 
nitrogen donor; phosphoserine phosphatase (PSPH) dephosphorylates p-Ser to 
yield serine. (B) In vitro PHGDH assay. Diaphorase couples the NADH produced 
upon PHGDH turnover to the reduction of resazurin to fluorescent resorufin. 
Resorufin fluorescence is a proxy for PHGDH activity. PSAT1 is included to 
prevent product feedback inhibition of PHGDH by p-Pyr. (C) Z-score plot for the 
800,000 compound library screened using above PHGDH assay. Each point 
represents a single compound. A negative score indicates inhibition. (D) Screen 
triaging strategy. Setting a Z score threshold of -3 gave 3,906 putative hits. After 
counter-screening against diaphorase to rule out false positives and confirming 
activity against PHGDH 408 compounds remained. Selected compounds were 
profiled against a panel of metabolic NAD(P)+ dehydrogenases to ascertain 
selectivity for PHGDH. (E) Structures of representative PHGDH inhibitors 
evaluated in cell-based assays. 
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A triaging strategy based on hit potency and selectivity was designed. We 
reasoned that inhibitors specific to PHGDH would minimize general cellular 
toxicity compared to compounds that hit a variety of dehydrogenases. Thus, half 
maximal inhibitory concentrations (IC50) were determined for a panel of NAD(P)+ 
dependent dehydrogenases that included PHGDH, isocitrate dehydrogenase 
(IDH1), malate dehydrogenase (MDH1), and 3!-hydroxysteroid dehydrogenase 
(3!-HSD). Compounds at least 4-fold more selective for PHGDH were 
progressed for further analysis. Based on this triaging, seven of the most potent 
PHGDH inhibitors were selected as lead compounds for evaluation in cell-based 
assays; selected structures are shown (Figure A.1). A number of these 
compounds are likely to target sulfhydryl groups and may therefore react with a 
PHGDH cysteine residue. For example, both CBR-5807 and CBR-6936 contain 
sulfhydryl reactive disulfide centers. Interestingly, CBR-5807 (Disulfiram) is an 
approved drug dosed in humans to treat alcoholism and known to inhibit 
aldehyde dehydrogenase by reacting with sulfhydryl groups 18.  
 
CBR-5884 inhibits serine synthesis in cells.   
 
We determined whether any of our seven leads inhibited serine synthesis 
in cancer cells. To do so, we turned to gas chromatography mass-spectrometry 
(GCMS) with uniformly carbon-13 labeled glucose (13C6-glucose) tracing. Given 
the isotopic enrichment of serine, it is possible to decouple newly synthesized 
serine from extracellular serine or serine that was synthesized prior to tracer 
-'!
addition. Newly synthesized serine has a mass-shift of 3 (M+3) due to the 
incorporation of glucose-derived 13C via 3-PG. We first investigated the kinetics 
of serine labeling. Serine labeling plateaued around 6h with ~65% of the serine 
pool being 13C labeled. The plateau phase likely reflects exchange between intra- 
and extra-cellular serine pools 19.  
With an understanding of serine labeling kinetics, we designed a 13C6-
glucose tracing assay to acutely interrogate the effects of compounds on serine 
synthesis (Figure A.2). Assaying serine synthesis with a 3-hour compound 
treatment was preferred to longer treatments to guard against false positives that 
decrease serine labeling by an indirect effect, such as generally compromising 
cellular viability. Among our lead compounds, CBR-5884 was able to decrease 
de novo serine synthesis by 30%; the remaining compounds had little effect 
(Figure A.2). The dose at which CBR-5884 had an effect on serine labeling was 
consistent with the in vitro biochemical IC50 of 33 ±12µM for PHGDH (Figure 
A.2). At such concentrations, CBR-5884 had no effect on two other NAD+ 
dependent dehydrogenases, lactate dehydrogenase (LDH) and MDH1 (Figure 
A.2). Importantly, under the acute treatment time period used in the labeling 
assays, CBR-5884 was not generally cytotoxic at concentrations up to 40µM as 
determined by two independent cellular viability assays. Hence, decreases in 
serine labeling are a direct effect of CBR-5884 mediated PHGDH inhibition.  
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Figure A.2. CBR-5884 inhibits serine synthesis in cells. (A) Acute inhibitor 
treatment assay schematic. Carney cells are pre-treated with drug at 30µM for 1h 
prior to initiating 13C6-glucose labeling for 2h still in the presence of drug. Polar 
metabolites are harvested and analyzed by GC-MS. (B) The ability of the 7 lead 
PHGDH inhibitors to block serine synthesis was assayed as in (A). 13C6-glucose 
derived serine (M+3 serine) relative to total serine levels are plotted. (C) In vitro 
IC50 assays for PHGDH and lactate dehydrogenase, LDH. Initial rates of the 
enzymatic reaction (Vi) at the indicated CBR-5884 concentration normalized to 
that of the DMSO control (Vo) are plotted. (D) CBR-5884 dose response 
experiment as in (A) but monitoring a panel of phosphoserine pathway and 
glycolytic metabolites. Y-axes indicate the fraction of the indicated metabolite 
derived from glucose (M+3 metabolite level relative to total metabolite level). 
Asterisks indicate significant differences vs. DMSO treatment (p < 0.05, t-test, n " 
3). Error is given as ± 1SD.  
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 We resynthesized CBR-5884 in house and performed a dose response 
experiment for CBR-5884 employing the same acute treatment method as 
above. Serine labeling was significantly decreased at 30µM and trended towards 
a decrease at 15µM (Figure A.2). Importantly, perturbations in labeling were 
specific to serine in that neither the PHGDH substrate, 3-PG, nor the end 
products of glycolysis, pyruvate and lactate were affected (Figure A.2). We 
further confirmed that glycolytic metabolites were unperturbed by CBR-5884 
treatment using LC-MS/MS to interrogate a greater panel of metabolites. Thus, 
changes in serine labeling are a direct effect of CBR-5884 mediated PHGDH 
inhibition and not a consequence of changes in PHGDH substrate levels or 
general perturbations in glycolytic flux (Figure A.2). The absence of an effect on 
lactate labeling was consistent with the in vitro data showing that CBR-5884 does 
not inhibit LDH under the drug concentrations used. In sum, the data argue that 
CBR-5884 is able to selectively inhibit serine synthesis in cells. 
Given that CBR-5884 is an ethyl ester and therefore susceptible to 
intracellular esterases, we investigated whether the carboxylic acid derivative of 
the parent molecule was still active against PHGDH; were the acid less active, it 
would likely decrease the efficiency of targeting PHGDH in situ. Parent and acid 
derivatives were equally potent against and selective for PHGDH in vitro 
suggesting that intra-cellular de-esterification is unlikely to affect CBR-5884 
activity. 
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CBR-5884 selectively inhibits the proliferation of cancer cells with a high 
propensity for serine synthesis.  
 
We established a system to test the ability of CBR-5884 to inhibit PHGDH-
dependent cancer cell proliferation. We first evaluated the ability of a panel of 
breast and melanoma cell lines to proliferate in serine replete or deplete media 
as a proxy for serine biosynthetic activity. Breast lines were selected based on 
PHGDH expression according to the Cancer Cell Line Encyclopedia (CCLE) data 
and validated by blotting for PHGDH (Figure A.3) 20. Removing extracellular 
serine had no effect on proliferation of high PHGDH expressing lines: MDA-MB-
468, MDA-MB-436, HCC70, and Hs578T (Figure A.3). All four lines cluster in the 
top quartile of the CCLE data set for PHGDH expression; MDA-MB-468 and 
HCC70 cells harbor PHGDH amplifications 14. In contrast, serine depletion 
almost completely abrogated proliferation of low PHGDH expressing lines: MDA-
MB-231 and MCF10A (Figure A.3). In melanoma cells, PHGDH protein levels 
were similarly commensurate with the ability to proliferate in serine free media. 
Interestingly, although Carney cells are sensitive to extracellular serine depletion, 
they can adapt and proliferate as evidenced by increased PHGDH protein levels 
upon serine depletion.  
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Figure A.3. CBR-5884 selectively inhibits the proliferation of breast cancer 
lines with a high propensity for serine synthesis. (A) Western blot for lines 
grown in +SER media; 2 lanes per cell line with each lane loaded with 
independent cell lysates. (B) Proliferation assay for breast lines grown in either 
serine replete (+SER) or deplete (-SER) media. Proliferation assay for lines 
treated with CBR-5884 in (C) +SER or (D) -SER media. Proliferation assay for 
lines grown in (E) +SER or (F) -SER media with PHGDH knockdown (sh1 & sh2) 
or a nontargeting control (shGFP). MDA-MB-468 and HCC70 are PHGDH 
amplified. MCF-10A cells are non-transformed mammary epithelial cells, other 
lines are cancer cell lines. MDA-MB-231 and MCF-10A lines were not included in 
–SER experiments in (D) and (F) because they are sensitive to serine 
withdrawal. Histograms depict mean ± standard error (n " 3).  
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Given that the ability to proliferate in the absence of extra-cellular serine is 
indicative of a high propensity for serine synthesis, we hypothesized that such 
lines should be sensitive to CBR-5884. Conversely, lines that cannot grow in 
serine free media have a low propensity for serine synthesis and should 
therefore be resistant to PHGDH inhibition. Treating the breast lines with CBR-
5884 in serine replete media inhibited growth of the four lines that grew without 
extra-cellular serine in a dose dependent manner with growth inhibition ranging 
from 35% to 60% at 30µM CBR-5884. The inhibitor had no effect on the three 
lines sensitive to serine withdrawal indicating that the inhibitor was selectively 
toxic to cells with high serine synthesis activity (Figure A.3). We next asked 
whether removing serine from the media, to enhance the reliance on de novo 
serine synthesis, could sensitize cells to PHGDH inhibition. Indeed, serine 
depletion increased the efficacy of CBR-5884 in lines already sensitive under 
serine replete conditions as evidenced by an 80% to 90% decrease in 
proliferation with 30µM CBR-5884 (Figure A.3). Moreover, MCF7 cells, which 
were of intermediate sensitivity to serine withdrawal, and insensitive to drug 
under serine replete conditions, became partially sensitive to the inhibitor under 
serine deplete conditions (Figure A.3). Importantly, under serine replete 
conditions, PHGDH knockdown phenocopied the effects of CBR-5884 treatment 
in that the drug-sensitive lines were also sensitive to PHGDH knockdown (Figure 
A.3). Furthermore, as with the drug treatments, growing cells in serine free media 
enhanced the growth inhibitory effect of PHGDH knockdown (Figure A.3). Similar 
trends were observed for the melanoma panel in terms of both the selectivity of 
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CBR-5884 for cells with a high propensity for serine synthesis and the increased 
efficacy under serine deplete conditions. Finally, the acid derivative of compound 
588-4 was not effective on MDA-MB-468 cells likely owing to poor membrane 
permeability and is therefore not a viable alternative to the parent compound.  
 
Analysis of CBR-5884 inhibition modality.  
 
We sought to more deeply characterize the mechanism by which CBR-
5884 inhibits PHGDH. Inhibition constants (Ki) for CBR-5884 with respect to each 
substrate were determined. CBR-5884 inhibited PHGDH in a non-competitive 
mode with respect to both substrates, as evidenced by a decreasing Vmax with 
increasing CBR-5884 concentration. The inhibition constants were 50 ±20µM and 
50 ±3µM for 3PG and NAD+, respectively (Figure A.4). We assessed whether 
there was any time dependence to the onset of inhibition by varying the time 
period for which drug and PHGDH were pre-incubated before initiating the 
enzymatic reaction. CBR-5884 was progressively more potent with increasing 
pre-incubation time culminating in an IC50 of 7µM when drug and PHGDH were 
pre-incubated for 4 hours (Figure A.4). Intrigued by the combination of a time 
dependent onset of inhibition and non-competitive inhibition, the latter suggesting 
that CBR-5884 might be binding to an allosteric pocket, we speculated that CBR-
5884 could be affecting the PHGDH oligomerization state, where the time 
dependency of inhibition could potentially stem from drug-induced conformational 
changes in PHGDH. To evaluate the PHGDH oligomerization state, we incubated 
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PHGDH with drug and then cross-linked prior to SDS-PAGE. CBR-5884 shifted 
the PHGDH equilibrium from the tetrameric to the dimeric state (Figure A.3). No 
such effect was observed with LDH which is resistant to CBR-5884 mediated 
inhibition. CBR-5884 still inhibited a truncated form of PHGDH, which lacks the 
C-terminal domain responsible for tetramerization and is therefore a constitutive 
dimer. Together these results suggest that disruption of the tetramer might assist 
PHGDH inhibition, but is not necessary for inhibition.   
  
%.%!
 
 
Figure A.4. Mechanisms of CBR-5884 inhibition. Inhibition constants (Ki) were 
determined by titrating (A) 3PG or (B) NAD+ while holding the other substrate 
constant at 4 different CBR-5884 concentrations and determining the initial 
reaction rate using a PHGDH assay. Plots were fit to a non-competitive model. 
(C) Time dependent inhibition was measured by preincubating drug and PHGDH 
for 0.5h, 1h, or 4h as indicated prior to initiating the PHGDH reaction. Initial 
reaction rates (Vi) were determined and normalized to that of DMSO (Vo). (D) 
PHGDH was preincubated with CBR-5884 (0, 50, 200, or 400µM) prior to 
crosslinking with BS3 (0.25 or 2.5mM) followed by SDS-PAGE and coomassie 
staining. Left-most lane had no BS3 indicating the monomeric species. 
Oligomerization state was inferred from reference to a molecular weight ladder.  
Error is given as ± 1SD (n " 3). 
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Discussion 
 
 We have reported the discovery of a novel PHGDH inhibitor, CBR-5884, 
and shown that it inhibits serine synthesis in cells. Furthermore, CBR-5884 
specifically inhibited the proliferation of melanoma and breast cancer lines with 
high levels of serine synthesis activity with little effect on lines reliant on serine 
import. Thus, CBR-5884 is selective for lines addicted to serine synthesis and 
phenocopies sensitivity to PHGDH knockdown. Finally, a biochemical analysis of 
CBR-5884 revealed that it was a non-competitive inhibitor that showed a time 
dependent onset of inhibition and disrupted the oligomerization state of PHGDH.  
Recent work examining how malignant cells rewire their metabolism to 
support growth and proliferation has revealed a number of clinically interesting 
targets 21,22. Perhaps the most promising is the discovery of gain-of-function 
mutations in the isocitrate dehydrogenase (IDH) enzymes that result in the 
production of the oncometabolite 2-hydroxyglutarate 23,24. The findings translated 
into chemical probes that yielded insights into the biology of IDH mutations 25,26 
and led to clinical programs (eg. NCT02481154). The genetic evidence pointing 
to a role for PHGDH in cancer is similarly striking: PHGDH is one of few 
metabolic enzymes genetically deregulated in cancer 27,28. Notably, elevated 
PHGDH expression correlates with clinical aggressiveness and poor prognosis in 
TNBC 13,16 and NSCLC 15. There is a paucity of targeted therapies for these 
cancers and chemotherapies remain mainstay 29,30. Thus, the clinical potential of 
PHGDH inhibitors as targeted agents for TNBC and NSCLC tumors addicted to 
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serine synthesis, as a single agent or in combination with standard of care, is an 
exciting perspective.  
 Beyond the preclinical applications, a PHGDH inhibitor provides a new 
tool to study de novo serine synthesis. For example, it remains unclear why a 
serine biosynthesis enzyme is critical for tumor growth when serine is available in 
the serum 13,14. CBR-5884 provides a valuable tool complementary to genetic 
strategies to study this and other phenomena as small molecules provide greater 
temporal resolution and do not deplete the actual protein. Moreover, CBR-5884 
has already suggested an interesting feature of PHGDH biochemistry, namely 
that human PHGDH could be regulated by transitions between different 
oligomerization states. These findings are reminiscent of pyruvate kinase M2 
(PKM2) regulation in that both an endogenous metabolite, fructose-1,6-
bisphosphate, and pharmacological small molecule activators enhance PKM2 
activity by stabilizing the tetrameric form 31,32. Endogenously, 2-phosphoglycerate 
(2PG) has been reported to activate PHGDH 33. Mechanistically, 2PG could be 
functioning by modulating the PHGDH oligomerization state. Finally, it is possible 
that CBR-5884 is a covalent inhibitor of PHGDH. While PHGDH does not rely on 
an active site cysteine, there are a number of cysteines that could potentially 
perturb enzymatic function were they modified since they are in close proximity to 
the active site (PDB: 2G76). In an attempt to determine whether changes in 
PHGDH oligomerization state are unique to CBR-5884, it would be interesting to 
determine whether Disulfiram (CBR-5807), CBR-6936, or sulfhydryl blocking 
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reagents have similar effects. Mechanistic studies, including those described 
above, are ongoing.  
The identification of a selective novel small molecule inhibitor of PHGDH 
capable of modulating de novo serine synthesis in PHGDH-dependent cancer 
cells represents a significant step towards the goal of targeting cancer 
metabolism in oncology. However, future in vivo evaluation of the CBR-5884 
chemical series will require medicinal chemistry-based optimization. Indeed, 
CBR-5884 was found to be unstable in mouse plasma and, as described, 
replacement of the ethyl ester moiety with the corresponding negatively charged 
carboxylic acid resulted in a derivative that retains enzyme inhibitory activity but 
loses activity on cells. Thus, CBR-5884 is more likely to serve as a tool 
compound, and as a starting point for generating more drug-like molecules, than 
an actual drug. Efforts aimed at identifying cell permeable plasma-stable 
derivatives are ongoing. Furthermore, the cell-based potency of this series will 
likely need to be improved to enable in vivo evaluation at exposure levels that are 
not generally toxic. Medicinal chemistry approaches aimed at optimizing the 
potency and ADME properties of CBR-5884 are ongoing. Nevertheless, our 
results provide a proof-of-concept that small molecule inhibitors of PHGDH 
represent a viable new class of anti-cancer drugs.  
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Methods 
 
Cells, transfections, and infections: Breast and melanoma lines were 
passaged in RPMI supplemented with: 10% FBS, penicillin, streptomycin, and 
normocin (InvivoGen). Lentivirus was produced from Lenti-X 293T cells 
(Clontech) transfected with packaging plasmids pCMV-dR8.2 and pCMV-VSV-G 
and indicated pLKO.1 shRNAs: PHGDH, TRCN0000233029 (sh1) 
and TRCN0000221864 (sh2); nontargeting control, TRCN0000072181 (shGFP). 
Experiments were performed in compliance with the Institutional Biosafety 
Committee. See SI Methods for details.  
 
Immunoblots: Protein was extracted from cells via trichloroacetic acid 
precipitation and blotted for with primary antibodies: !PHGDH (Sigma 
HPA021241, 1/10000); !Vinculin (Sigma V9264, 1/5000). See SI Methods for 
details.  
 
Proliferation assays: Cells were plated at a low density in 96 or 24 well plates in 
serine containing media. The following day, media was aspirated, cells were 
washed with PBS, and fresh serine replete or deplete media containing drug 
(15µM, 30µM) or vehicle (DMSO) was added. Cells were grown for 3 to 5 days, 
with drug and media changed daily before assaying relative cell numbers. See SI 
Methods for details.  
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Acute drug treatments with 13C6-glucose tracing: Carney cells acclimated to 
growth in MEM (Corning) were plated at 9#105 cells per 6cm dish the night 
before. The following morning, media was replaced with fresh media containing 
CBR-5884 (1µM, 15µM, 30µM,) or vehicle control (DMSO) for 1h. Media was 
then aspirated, cells were washed with PBS, and fresh glucose free MEM 
(Gibco) supplemented with 13C6-glucose (3g/L, Cambridge Isotopes) and 10% 
dialyzed FBS containing drug or DMSO was added. After 2h, cells were quickly 
washed with cold PBS on ice and flash frozen. Polar metabolites were extracted 
as in the GCMS methods. See SI Methods for details. 
 
Acute toxicity assay: Carney cells acclimated to growth in MEM media were 
plated in a 96 well plate at 6,000 cells/well. The next day, cells were treated with 
CBR-5884 from 1µM to 40µM for 3h. Drug containing media were then removed, 
fresh drug-free media added, and cell viability was determined via a CellTiter-Glo 
(Promega G7572) or Alamar Blue (Invitrogen DAL1025) assay according to the 
manufacturer’s protocol. See SI Methods for details. 
 
GCMS metabolite analysis: Polar metabolites were extracted with 2ml 
MeOH/H2O (4:1) for 30min on dry ice, scraped, transferred to 2ml tubes, 
centrifuged (30min, 15000rpm), and the supernatants dried under vacuum. 
Samples were derivatized as previously described 34 and analyzed on an Agilent 
6890 GC instrument. Metabolite quantification was inferred from a standard 
curve and fractional enrichment of 13C in metabolites was corrected for the 
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natural abundance of 13C and 15N 35,36. See SI Methods for details. 
 
LC-MS/MS metabolite analysis:  Polar metabolites were extracted and dried as 
in the GCMS method. Samples were resuspended in 15µl of HPLC grade water. 
5µl of each sample was injected and analyzed using a 5500 QTRAP triple 
quadrupole mass spectrometer (AB/Sciex) coupled to a Prominence UFLC 
system (Shimadzu) as reported previously 37 
 
Protein purification: His6-tagged pET28a PHGDH, pET28a PSAT1, and 
pNIC28-Bsa4 PHGDH3-314 were purified via nickel agarose (Qiagen) from BL21 
E. coli cultures. pVB-CBD IDH1 was purified via Macroporous Bead Cellulose 
capture,  TEV protease (Sigma-Aldrich) digestion, and gel filtration 
chromatography from  BL21 E. coli cultures. See SI Methods for details. 
 
PHGDH assays: PHGDH activity was measured in 96-well plates by monitoring 
NADH fluorescence (Ex340nM/ Em460nM) over time. PSAT1 was included to 
prevent product inhibition of PHGDH. See SI Methods for details. 
 
LDH and MDH1 assays:  Enzyme activities were assayed using kits (LDH: 
Sigma MAK06; MDH1: Sigma MAK196-1KT) according to the manufacturer’s 
instructions with commercially available recombinant enzyme (LDH: Sigma 
59747; MDH1: Sigma SRP6103). Drug, titrated as for the PHGDH IC50 assays, 
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and enzyme were pre-incubated for 30min prior to initiating reaction with 
substrate  
 
Cross-linking assays: PHGDH (1.5µg) or LDH (2.2µg, Sigma 59747) were 
incubated with CBR-5884 (50µM, 200µM, 400µM) or vehicle control (DMSO) in 
25mM HEPES, pH 7.3, and 1mM NAD+ in 18µL total volume for 30min prior to 
BS3 (Pierce) cross-linking and quenching. Samples were run on SDS-PAGE and 
colloidal coomassie stained (Bio-Rad). See SI Methods for details. 
 
Primary PHGDH screen, diaphorase counter screen, and dehydrogenase 
panel selectivity profiling: 800,000 compounds were screened at a single dose 
(13.3µM) in 1536-plate format against PHGDH or diaphorase quantifying 
resorufin fluorescence (550/590nm; Ex/Em) with an Envision plate reader. 
Results were analyzed using Genedata Screener software. Compounds with a 
robust Z-score < -3 in the PHGDH screening assay and robust Z-score > -2 in 
the diaphorase counter screen were selected as hits. See SI Methods for 
detailed protocol, hit selection and confirmation, and selectivity profiling against 
dehydrogenase panel. 
 
Chemical syntheses: CBR-5884, ethyl 5-(furan-2-carboxamido)-3-methyl-4-
thiocyanatothiophene-2-carboxylate, and the acid derivative, 5-(furan-2-
carboxamido)-3-methyl-4-thiocyanatothiophene-2-carboxylic acid, synthesis was 
adapted from the literature as described in SI methods 38,39.  
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Cancer. 
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Tumours have high energetic and anabolic needs for rapid cell growth and 
proliferation1, and the serine biosynthetic pathway was recently identified as an 
important source of metabolic intermediates for these processes2,3. We 
integrated metabolic tracing and transcriptional profiling of a large panel of non-
small cell lung cancer (NSCLC) cell lines to characterize the activity and 
regulation of the serine/glycine biosynthetic pathway in NSCLC. Here, we show 
that the activity of this pathway is highly heterogeneous and is regulated by 
NRF2, a transcription factor frequently deregulated in NSCLC. We found that 
NRF2 controls the expression of the key serine/glycine biosynthesis enzymes 
PHGDH, PSAT1 and SHMT2 via ATF4 to support glutathione and nucleotide 
production. Moreover, we show that expression of these genes confers poor 
prognosis in human NSCLC. Thus, a substantial fraction of human NSCLC 
activates a NRF2-dependent transcriptional program that regulates serine and 
glycine metabolism and is linked to clinical aggressiveness.   
Uniformly labelled 13C-glucose ([U-13C] glucose) is metabolized via the 
glycolytic intermediate 3-phosphoglycerate to serine M3 (three 13C-labelled 
atoms) and, subsequently, to glycine M2 (two 13C-labelled atoms) through the 
combined action of the serine biosynthetic pathway and serine 
hydroxymethyltransferase4 (Figure B.1). To profile the activity of the 
serine/glycine biosynthesis pathway in NSCLC, we labelled a panel of 79 human 
NSCLC cell lines with 13C-glucose and quantified serine and glycine labelling via 
gas chromatography/mass spectrometry (GC/MS). We determined 6 and 24 
hours to be the optimal time points to detect labelling in serine and glycine 
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(Supplementary Figure 1). After 24 hours, the fractional abundance of serine M3 
and glycine M2 ranged from 0–40% (Figure B.1), with significant correlation 
between the time points. Neither serine nor glycine labelling correlated with 
cellular doubling times. There was a significant correlation between serine M3 
and glycine M2 labelling at both time points, indicating that the glycine produced 
from glucose was derived from serine (Figure B.1). As has been reported 
previously3, de novo serine synthesis conferred the ability to grow in the absence 
of extracellular serine (Figure B.1). Thus, the serine biosynthesis pathway is not 
uniformly operant in NSCLC, and regulatory mechanisms exist for controlling the 
activation of this pathway in a subset of cell lines.  
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Figure B.1: Serine biosynthesis activity in lung cancer. (a) Synthesis of 
serine and glycine from glucose. Glycolytic metabolism of uniformly labelled 13C-
glucose (U-13C-glucose) produces 3-phosphoglycerate (3-PG) labelled on all 3 
carbons (M3). The serine biosynthetic pathway produces serine (M3, 3 carbons 
labelled), and subsequently glycine (M2, 2 carbons labelled) from 3-PG. 
Unlabelled (M0) serine and glycine are contributed from the cellular media. (b, c) 
Fraction of labelled intracellular serine (b) and glycine (c) at 6 and 24 hours in 
NSCLC cell lines. Cell lines are ordered according to serine M3 labelling at 6 
hours. (d, e) Correlation between serine and glycine labelling at 6 (d) and 24 (e) 
hours. R=Pearson correlation coefficient. p-values were calculated by Student’s 
t-distribution with n–2 degrees of freedom. (f–g) Serine 'high' cells (serine M3 Z-
score > 0.5 at 24 hours) are resistant to serine (f) or serine/glycine (g) starvation 
for 3 days. Each data point represents a cell line. (h) Serine labelling at 24 hours 
correlates with PHGDH mRNA expression. mRNA expression data was obtained 
from the CCLE. Each data point represents a cell line. (i) Serine ‘high’ cell lines 
demonstrate sensitivity to PHGDH knockdown that is not rescued by serine. 
Relative cell number was quantified 5 days after PHGDH knockdown. Each data 
point represents a cell line. (j) H1975 cells expressing luciferase (LUC) or 
PHGDH were assayed as in (f–g). Results are the average of 3 biological 
replicates. Error bars represent SEM here and for all figures.  
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Figure B.1 (Continued) 
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To reveal a mechanism for increased serine biosynthesis in NSCLC, we 
correlated serine and glycine biosynthesis with gene expression using data from 
the Broad-Novartis Cancer Cell Line Encyclopedia5. We observed a significant 
correlation between serine and glycine labelling and the expression of PHGDH 
(Figure B.1), the first and rate-limiting step in serine biosynthesis4. “Serine-high” 
cells (serine M3 Z-score > 0.5 at 24 hours) were sensitive to PHGDH silencing 
(Figure B.1) and ectopic PHGDH rescued the proliferation of serine-low cell lines 
in serine-deficient media (Figure B.1). Previous studies have revealed a role for 
PHGDH copy number gain in increasing serine biosynthetic activity2,3. However, 
we did not see evidence for this mechanism in NSCLC cell lines. To investigate 
alternative mechanisms of PHGDH regulation, we performed gene set 
enrichment analysis (GSEA6,7) on the genes that positively correlated with serine 
and glycine biosynthesis. Interestingly, targets of the transcription factor nuclear 
factor erythroid-2–related factor 2 (NRF2, gene name NFE2L2) were the top hit, 
suggesting that NRF2 may be a regulator of PHGDH and the serine biosynthetic 
pathway. 
Next, we examined NRF2 localization and found a significant correlation of 
nuclear NRF2 with serine biosynthesis (Figure B.2). Additionally, we ranked 
these cell lines according to expression of NRF2 target genes, which significantly 
correlated with NRF2 abundance. NRF2-high cell lines had significantly higher 
serine M3 labelling at 6 and 24 hours, and glycine M2 labelling at 24 hours 
(Figure B.2). Next, we silenced NRF2 and found that it regulates serine/glycine 
biosynthetic pathway gene expression (PHGDH, PSAT1, PSPH, SHMT1, and 
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SHMT2) (Figure B.2). Decreased PHGDH and PSAT1 mRNA was accompanied 
by lower protein levels (Figure B.2). Furthermore, NRF2 or PHGDH knockdown 
decreased the production of 13C-serine from 13C-glucose (Figure B.2). These 
results demonstrate that transcriptional regulation of serine biosynthetic enzymes 
by NRF2 controls the production of serine from glucose.  
ATF4 transcriptionally activates serine biosynthetic genes in response to 
serine starvation in NSCLC cells8. Interestingly, nuclear ATF4 expression 
correlated with both serine labelling and NRF2 protein expression. ATF4 has 
been reported as both a direct transcriptional target9,10 and heterodimerization 
partner11,12 of NRF2. In agreement with transcriptional regulation, we observed a 
marked reduction in ATF4 mRNA expression, binding of RNA polymerase II to 
the ATF4 promoter, and levels of newly synthesized ATF4 mRNA upon NRF2 
silencing (Figure B.3), with no effect on ATF4 mRNA stability. Furthermore, ATF4 
protein was decreased upon NRF2 knockdown (Figure B.3), but NRF2 did not 
regulate ATF4 translation13. Notably, ATF4 knockdown reduced the expression 
and activity of the serine pathway to an extent similar to that seen with NRF2 
knockdown, while it did not affect NRF2 expression (Figure B.3). Ectopic 
expression of NRF2 in NRF2-depleted cells partially rescued NQO1, ATF4 and 
serine biosynthesis enzyme expression and induced expression of these genes 
in the serine-low cell line H1975, confirming the regulation of these genes by 
NRF2. Similarly, ectopic ATF4 expression rescued the effects of NRF2 silencing 
on serine biosynthesis enzyme expression (Figure B.3), and serine labelling from 
glucose at early time points (Figure B.3), although defects in serine production 
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were observed later. Furthermore, ectopic ATF4 rescued the growth of H1975 
cells in serine deficient media (Figure B.3). We identified the ATF4 binding sites 
in the PHGDH, PSAT1 and SHMT2 promoters, and found that, while NRF2 itself 
did not bind to these sites, its silencing significantly decreased binding of ATF4 
(Figure B.3). These results demonstrate that NRF2 regulates serine biosynthesis 
gene expression through ATF4.  
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Figure B.2: NRF2 regulates serine biosynthesis. (a) Nuclear NRF2 protein 
expression correlates with 13C-serine M3 labelling at 24 hours. Nuclear NRF2 
protein expression data is found in Supplementary Figure 7. (b) Cell lines with 
high NRF2 activity have significantly higher 13C serine M3 labelling at 6 and 24 
hours. Cell lines were grouped according to the NRF2 score into “high” (>1.4) 
and “low” (<1.4). (c) NRF2 high cell lines have significantly higher 13C glycine M2 
labelling at 24 hours. (b,c) p-values were calculated using an unpaired, two-tailed 
student’s t-test. (d) mRNA expression in A549 cells expressing scramble shRNA 
(SCR) or NRF2 shRNA #1. Decreased NQO1 expression confirmed that NRF2 
activity was reduced upon knockdown. Results are the average of 3 technical 
replicates. (e) Western blot of serine pathway enzyme expression in lysates from 
A549 cells expressing scramble (SCR), or NRF2 shRNAs #1 or #2.  (f) Cell lines 
were grown in the presence of U-13C-glucose for the indicated time points, the 
metabolites extracted and the fractional 13C-labelling on serine analysed by 
LC/MS. Results are the average of 3 biological replicates.   
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Figure B.3: NRF2 regulates the expression of serine/glycine biosynthesis 
genes through ATF4. (a) ATF4 mRNA expression in A549 cells expressing 
scramble shRNA (SCR), or NRF2 shRNA #1. (b) Western blot of NRF2, ATF4 
and ACTIN expression in cells from (a). (c) Western blot of NRF2, ATF4 and 
serine pathway enzyme expression in lysates from A549s expressing scramble 
(SCR), NRF2 shRNA #1, or ATF4 shRNAs #1 or #2. (d) mRNA expression in 
cells from (c). (e) ATF4 knockdown impairs serine biosynthesis. Cell lines from 
were grown in the presence of U-13C-glucose for the indicated time points, the 
metabolites extracted and the fractional 13C-labeling on serine analysed by 
LC/MS. (f) ATF4 rescues serine biosynthesis enzyme expression following NRF2 
knockdown. A549 cells were infected with lentivirus encoding mATF4 prior to 
infection with scramble or NRF2-targeting lentivirus. (g) Western analysis of 
NRF2, ATF4, and ACTIN expression in the cells from (f). (h) ATF4 rescues the 
serine biosynthesis defect in shNRF2 A549 cells. Cells were assayed as in (e). (i) 
ATF4 rescues the growth of H1975 cells in serine deficient media. Cells 
expressing luciferase (LUC) or ATF4 were grown in the indicated media for 3 
days and cell number normalized to cells grown in full media. (j) Chromatin 
immunoprecipitation of ATF4 to the PHGDH, PSAT1 and SHMT2 promoters. 
Samples were normalized to IgG control immunoprecipitations. Results are the 
average of 3 technical (a, d, f, j) or biological (e, h, i) replicates.  
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Figure B.3 (Continued) 
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We examined how PHGDH-derived serine contributes to downstream 
metabolism (Figure B.4). PHGDH, NRF2 or ATF4 silencing decreased the 
incorporation of glucose-derived serine into cystathionine and glucose-derived 
glycine into glutathione (Figure B.4), without loss of cell viability. Metabolism of 
serine to glycine results in the production of one-carbon units via the folate cycle 
that are utilized for purine and thymidine synthesis (Figure B.4). We observed a 
decrease in the PHGDH-derived labelling (M+7) of purines including IMP, AMP, 
ADP, and inosine following PHGDH or ATF4 silencing, while NRF2 silencing 
decreased both the ribose (M+5) and PHGDH-derived (M+7) labelling of these 
purines (Figure B.4). Serine-high cell line labelling in glutathione and purines was 
significantly higher at 48 hours than 24 hours (Figure B.4). Furthermore, the 
majority of the 13C-labelled serine and glycine had escaped the cell by 24 hours 
of 13C-glucose labelling due to equilibration with unlabelled amino acids in the 
media, suggesting that the fraction labelling at 24 hours was underestimating the 
total contribution of PHGDH to these metabolite pools. In support of this notion, 
PHGDH, NRF2 or ATF4 silencing resulted in significant decreases in the total 
levels of purines and thymidine nucleotides (Figure B.4) as well as glutathione, 
cystathionine and homocysteine (Figure B.4). In contrast, we did not observe 
differences in the S-adenosyl methionine (SAM)/S-adenosyl homocysteine (SAH) 
ratio, which is also modulated by the folate cycle, or in histone or DNA 
methylation. Furthermore, we observed a significant decrease in the 
NADPH/NADP+ ratio in serine-high cells following PHGDH silencing that was not 
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observed in serine-low cells (Figure B.4). These results demonstrate that the 
serine biosynthesis pathway supports glutathione and nucleotide production in 
NSCLC.  
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Figure B.4: PHGDH-derived serine supports the transsulfuration and folate 
cycles. (a) Serine metabolism via the transsulfuration and folate cycles. 13C-
labelled carbons (l) unlabelled carbons (
!
). Gly: Glycine, Ser: Serine, CTH: 
Cystathionine; HCY: Homocysteine, GSH: Glutathione, gGC: g-glutamyl 
cysteine, Glu: Glutamate. (b–e) A549 cells expressing scramble (SCR), NRF2 or 
PHGDH shRNAs were grown in the presence of U-13C-glucose for 24 hours and 
metabolites were extracted and analysed by LC/MS. (b) Analysis of 13C-labelling 
on the glycine component of glutathione. (c) Analysis of 13C-labeling on the 
purine metabolite adenosine monophosphate (AMP). (d,e) Analysis of 
glutathione (d) and AMP (e) labelling in serine high cell lines. Cells were labelled 
with 13C-glucose for 24 or 48 hours as indicated. (b,d) PHGDH-derived serine is 
incorporated into glutathione through the generation of glycine and cysteine. M+0 
denotes no carbons labelled, M+2 denotes labelling on the glycine moiety, M+3 
denotes labeling on the cysteine moiety, and M+5 denotes labeling on both 
glycine and cysteine. M+5 labeling was not observed. (c,e) M+5 labelling occurs 
following ribose-5-phosphate labelling via the pentose phosphate pathway. M+7 
labelling is the result of ribose labelling plus either glycine or formyl-THF labelling 
in the purine ring. M+9 labelling is the result of ribose labelling plus either glycine 
and formyl-THF labelling in the purine ring. M+0 has no labelled carbons. (f–g) 
LC/MS analysis of total metabolite levels in the nucleotide (f) and transsulfuration 
(g) pathways. (h) NADPH/NADP+ ratios 4 days after PHGDH knockdown. 
Results are the average of 3 biological replicates.  
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Figure B.4 (Continued) 
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We next asked whether this pathway promotes tumourigenesis. PHGDH 
silencing significantly impaired the soft agar growth of serine-high, but not serine-
low, cell lines (Figure B.5). Interestingly, we observed a significant correlation 
between serine and glycine labelling and colony number in soft agar (Figure B.5). 
Furthermore, PHGDH silencing impaired the xenograft growth of the serine-high 
cell line PC9 (Figure B.5) but not the serine-low cell line H1373 (Figure B.5). We 
observed that all tumours re-expressed PHGDH at endpoint (Figure B.5), 
suggesting that PHGDH was required for tumour formation. Next, we examined 
whether serine pathway gene expression correlated with overall survival of 
human patients. Human tumours with high NRF2 protein expression displayed 
significantly higher expression of ATF4, PHGDH, PSAT1, and SHMT2 mRNA 
(Figure B.5), and vice versa. Furthermore, we found that high expression of 
PHGDH, PSAT1 and SHMT2 conferred a significantly poorer prognosis (Figure 
B.5) and was associated with higher tumour grade. These results demonstrate 
that in human NSCLC, NRF2 regulates the expression of serine biosynthetic 
enzymes, which correlates with poor prognosis. 
We have demonstrated a striking heterogeneity in the activity of the serine 
biosynthetic pathway in NSCLC. Notably, intracellular amino acid labelling from 
13C-glucose is underestimated because of rapid exchange with 12C-amino acids 
from the media, which is likely mediated by amino acid antiporters (see 
Supplementary Note). Caution should be used when interpreting data from 13C-
labelling experiments due to these exchange mechanisms. 
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Figure B.5: Activation of the serine biosynthesis pathway promotes 
tumourigenesis in NSCLC. (a) PHGDH knockdown impairs soft agar growth of 
serine high, but not serine low, cell lines. (b–c) Soft agar growth correlates with 
serine (b) and glycine (c) labelling at 24 hours. Each cell line was plated at 5,000 
cells/well and the number of colonies counted after 14 days. (d) PHGDH 
knockdown impairs the xenograft growth of a serine high cell line (PC9, left) but 
not a serine low cell line (H1373, right). Results are the average of 5 tumors. (e) 
Western analysis of PHGDH expression of cell lines and xenografts from (d) 
upon injection and at endpoint. (f) Patients with high NRF2 protein expression (Z-
score > 0.5) demonstrate elevated serine pathway gene expression in patient 
samples from TCGA lung adenocarcinoma cohort. Boxes represent mean 
values, error bars represent SEM. (g) Gene expression of PHGDH, PSAT1 and 
SHMT2 in the Director’s Consortium lung adenocarcinoma dataset clusters 
patients into high and low expression cohorts. (h) Kaplan-Meier survival analysis 
of patients with high (n = 29, red) or low (n = 414, blue) expression of PHGDH, 
PSAT1 and SHMT2 based on the patient clustering from (g). Median survival is 
36 (high) vs. 73.2 (low) months. The p-value was calculated using the Mantel-
Cox test.  
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Figure B.5 (Continued) 
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Heterogeneity of metabolic or signalling pathways is a common 
phenomenon across tumours, cell lines, and even between cells of the same 
tumour. Here, by systematically analysing the serine/glycine biosynthesis 
pathway in a large, highly-annotated panel of NSCLC cell lines, we identified 
NRF2 as the molecular driver of this pathway. NRF2 is frequently deregulated in 
NSCLC through somatic mutations that disrupt the NRF2–KEAP1 interaction to 
constitutively activate NRF214–18. Cancers with high NRF2 levels are associated 
with poor prognosis19,20, resistance to therapy and rapid proliferation18,21. 
Importantly, NRF2 ablation in various tumour models results in elevated ROS 
and the suppression of tumour growth in vivo21–23. However, the precise 
mechanism by which NRF2 promotes tumourigenesis is unclear. Recent studies 
have revealed that, in addition to genes that promote ROS detoxification, NRF2 
regulates genes involved in anabolic metabolism24,25. Here, we demonstrate that 
NRF2 regulates a serine biosynthesis metabolic program via ATF4 and PHGDH 
to supply the substrates for glutathione and nucleotide production (Figure B.6), 
which synergizes with the regulation of the pentose phosphate pathway to supply 
ribose for nucleotides24,25. NRF2 indirectly regulates ATF4 transcription via 
unknown mechanisms. Additionally, while ATF4 completely rescues PHGDH 
expression following NRF2 depletion, the partial rescue of other serine 
biosynthesis genes suggests that NRF2 regulates these genes combinatorially 
through ATF4 and additional factors. Furthermore, these findings suggest that 
multiple NRF2-regulated pathways co-ordinately contribute to tumourigenesis. 
Our work encourages the integration of metabolite tracing on large panels of 
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cancer cell lines in combination with gene expression analysis. This approach is 
a powerful tool for determining mechanisms responsible for differential regulation 
of metabolic pathways and may reveal additional links between the activity of 
metabolic pathways and genetic alterations in cancers. 
 
 
 
Figure B.6: Model of the regulation of serine/glycine biosynthesis by NRF2. 
An ATF4 transcriptional program, indirectly activated by NRF2/KEAP1 mutations, 
regulates the expression of serine/glycine biosynthesis enzymes. These 
enzymes produce serine and glycine from the glycolytic intermediate 3-PG and 
funnel the carbon into glutathione and nucleotides via the folate and 
transsulfuration cycles. NRF2/ATF4 regulated enzymes are shown in red. 3-PG: 
3-phosphoglycerate; 3-PP: 3-phosphohydroxy pyruvate; 3-PS: 3-phosphoserine; 
Ser: Serine; Cys: Cysteine; GSH: Glutathione. 
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Online Methods 
 
Animals. Male nude mice (CrTac:NCr-Foxn1nu) were obtained from 
Taconic labs and maintained under pathogen-free conditions. Experiments were 
performed according to IACUC guidelines. Mice were injected at 8 weeks of age 
with 2X106 NSCLC cells on each flank. shRNAs were randomized so they were 
evenly distributed across mice. As the animal study was exploratory, no 
statistical test was used to determine adequate sample size. No mice were 
excluded from the analysis. The study was not blinded. 
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Cell culture. All NSCLC cell lines used in this study were obtained from the 
Hamon Cancer Center Collection (University of Texas Southwestern Medical 
Center). Cells were maintained in RPMI-1640 (Life Technologies Inc.) 
supplemented with 5% or 10% fetal calf serum (FCS) without antibiotics at 37°C 
in a humidified atmosphere containing 5% CO2 and 95% air. All experiments 
were performed in media containing serine and glycine except where otherwise 
noted. All cell lines have been DNA fingerprinted using the PowerPlex 1.2 kit 
(Promega) and mycoplasma tested by the e-Myco (Boca Scientific) or MycoAlert 
kit (Lonza). Although NCI-H157 is listed in the database of commonly 
misidentified cell lines, it was originally derived by J.D.M. and fingerprinted before 
use.  
Celltox green staining. Cells were incubated in RPMI + 10% FCS 
containing 1X Celltox green (Promega) and 5 uM Syto 17 (Life Technologies) for 
20 minutes, washed in PBS, and imaged on an EVOS FL cell imaging system 
(Life Technologies).  
Chromatin Immunoprecipitation. Cells (5X106) were fixed at 37°C in RPMI 
with 1% formaldehyde for 10 min, lysed in 1% SDS, 10 mM EDTA, 50 mM Tris-
HCl pH 8.1 plus protease inhibitors and sonicated with a probe tip until DNA was 
an average size of 1 kilobase. Input was saved and lysate was diluted in 
immunoprecipitation buffer (1% Triton, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-
HCl pH 8.1) and mixed with beads (Dynal Protein A, Invitrogen) that were pre-
bound overnight with antibodies to Nrf2 (H-300, Santa Cruz), ATF4 (11815, Cell 
Signaling), RNA pol II (pSer5, ab5131, abcam) or Rabbit IgG (sc-2027, Santa 
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Cruz). Chromatin was immunoprecipitated overnight, and beads were washed six 
times with RIPA buffer (50 mM HEPES pH 7.6, 1 mM EDTA, 0.7% Na 
deoxycholate, 1% NP-40, 0.5 M LiCl) and twice with TE. Beads were incubated 
with 1% SDS, 0.1 M NaHCO3 for 30 min at room temperature, and then 
crosslinks were reversed on both the input and the immunoprecipitate by heating 
overnight in a 65°C water bath. DNA was purified with a QIAquick spin kit 
(Qiagen) and Q-PCR was performed in triplicate with a Fast Sybr green master 
mix on a Step One Real-Time PCR system (all Life Technologies). Primer 
sequences can be found in Supplementary Table 4.  
DNA methylation. DNA was extracted from cells in lysis buffer (10 mM 
Tris, 100 mM NaCl, 10 mM EDTA, 0.5% SDS, 0.4 mg/ml Proteinase K, pH 8.0) 
by heating overnight at 65°C. DNA was purified by precipitating protein with 
NaCl, and precipitated with isopropanol. 2 ug DNA was denatured in 0.4 M 
NaOH, 10 mM EDTA at 95°C for 10min and neutralized with an equal volume of 
2 M ammonium acetate, pH7.0. 200 ng of DNA was spotted on a nylon 
membrane (GE Healthcare), cross linked at maximum twice, and blocked in 5% 
milk for 1 hour. The membrane was incubated overnight with 5-meC antibody 
(clone 33D3; 1:1,000; Epigentek), followed by an HRP-secondary and 
chemiluminescence visualization. To ensure equal loading, the membrane was 
stained with 0.02% methylene blue in 0.3 M sodium acetate, pH 5.2. 5-meC 
intensity was normalized to methylene blue. 
GC/MS metabolite tracing. All NSCLC cell lines were cultured under 
identical conditions to identify cell-autonomous differences in glucose 
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metabolism. Cells were seeded into 60-mm culture dishes and grown until 70–
80% confluent. Each dish was then rinsed in warm phosphate-buffered saline 
and overlaid with 4 mL of RPMI-1640 containing 5% dialyzed fetal calf serum, 4 
mM unlabelled glutamine, and 10 mM [U-13C] glucose (Cambridge Isotope 
Laboratories). NB: RPMI-1640 contains unlabelled serine and glycine. After 6 
hours or 24 hours, the medium was aspirated and cells were rapidly rinsed in 
cold normal saline solution. The cells were lysed in 0.5 mL of cold 50% methanol, 
with three rapid cycles of freeze-thawing between liquid nitrogen and a 37oC 
water bath. The lysates were cleared of cellular debris by centrifugation, and 
metabolites in the supernatant were evaporated under blown air or by 
centrifugation under vacuum. Derivatization, mass spectrometry, and 
mathematical correction for natural abundance isotopes were performed 
according to published methods 26,27. The following fragments were monitored, 
which represent derivatized species: serine – m/z 306 (M+0) – 309 (M+3); 
glycine, m/z 276 (M+0) – 278 (M+2). Every cell line was analysed in biological 
replicates where n"3 and no two replicates were performed on the same day.   
Lentivirus production and infection. Lenti-X 293T cells (Clontech) were 
transfected at 90% confluence with Lipofectamine 2000 (Invitrogen). Packaging 
plasmids pCMV-dR8.2 dvpr (addgene # 8455) and pCMV-VSV-G (addgene 
#8454) were used with the vectors found in Supplementary Table 5. 
Viral supernatants were collected at 48 and 72 hours and added to target 
cells with 8mg/ml polybrene for 3 hours. Cells were selected in 1 mg/ml 
puromycin where appropriate.  
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LC/MS measurement of total and 13C-labeled metabolites in A549 cells. 
Cells were plated the day before labelling at 2X106 cells/10 cm dish and media 
was changed to glucose-free RPMI containing 10% dialyzed serum + 10 mM U-
13C-glucose (Cambridge Isotope Laboratories) for the indicated time points. 
Metabolites were extracted in ice-cold 80% methanol and analysed by targeted 
LC-MS/MS via selected reaction monitoring (SRM), as described28. The following 
precursor ions were monitored: serine – m/z 106 (M+0) and 109 (M+3); 
cystathionine – m/z 223 (M+0) and 226 (M+3); glutathione – m/z 308 (M+0), 
glutathione (G) – m/z 310 (M+2); homocysteine – m/z; 136; IMP – m/z 349 
(M+0), 354 (M+5) and 356 (M+7); inosine – m/z 267 (M+0), 272 (M+5), 274 
(M+7); AMP – m/z 348 (M+0), 353 (M+5) and 355 (M+7); dATP – m/z 490; dTTP 
– m/z 481; dTDP – m/z 401; dTMP – m/z 323 . The bracketed amino acid 
following glutathione indicates which constituent amino acid is 13C labelled. 
Samples were analysed in triplicate.  Data represents median-normalized values.  
Luciferase assays. Luciferase assays were performed with the Dual-Glo 
Luciferase Assay System (Promega) according to the manufacturer’s 
instructions. 
NADPH/NADP+ ratios. NADP+ and NADPH were determined with the 
NADP/NADPH-glo assay kit (Promega) according to the manufacturer’s protocol.  
NRF2 score calculation. Cell lines were grouped into high and low groups 
based on the expression of five classic NRF2 target genes: NQO1, GCLC, 
GLCM, SLC7A11, and AKR1C1. The expression of each gene was normalized to 
the median across the cell lines, and these five genes were then averaged 
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together.  NRF2 high vs. low was defined as the top quartile vs. bottom three 
quartiles. The top 20 overexpressed genes in the NRF2 high cell lines compared 
to the NRF2 low were used to calculate the NRF2 score: AKR1C1, AKR1C2, 
SPP1, ALDH3A1, LOC344887, AKR1C3, OSGIN1, PGD, CYP4F11, AKR1B10, 
KIAA0319, SRXN1, NR0B1, SLC7A11, LOC100292680, ABCC2, CABYR, 
JAKMIP3, KYNU and PTGR1. Gene expression values were normalized to the 
median and then these 20 genes were averaged together to get the NRF2 
score. Individual gene expression values and NRF2 scores can be found in 
Supplementary Table 3, and NRF2 high vs. low clustering is found in 
Supplementary Figure 8.  
Patient samples and survival analysis. The National Cancer Institute 
Director’s Challenge Consortium study (Director’s Consortium)29 and the Cancer 
Genome Atlas (TCGA) lung adenocarcinoma data were used in this study to 
evaluate gene signatures’ prognostic performance. The Director’s Consortium 
data set collected 442 resected lung adenocarcinomas at four US institutions29, 
while the TCGA Research Network data includes 203 patient samples for which 
gene expression and survival data are available. Unsupervised cluster analysis 
was used to group patients based on expression of PHGDH, PSAT1 and 
SHMT2, using average linkage clustering with the Spearman's rank correlation 
distance metric. Clustering was performed with Cluster 3.0. Heat map 
visualization was performed with JavaTreeView. Kaplan–Meier survival curves 
were used to determine survival rate as a function of time and survival 
differences were analysed by a log-rank Mantel-Cox test using Graph Pad Prism.  
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Proliferation assays. Cells were seeded at 500–10,000 cells/well in 96 well 
plates on day –1 and infected on day 0 with lentivirus. Alternatively, cells were 
switched into RPMI + 10% dialyzed FBS containing full amino acids, lacking 
serine, or lacking serine and glycine. Plates were fixed on the indicated days with 
4% paraformaldehyde, stained with crystal violet, washed and dried. Crystal 
violet was solubilized in 10% acetic acid and the OD600 was measured.  
Pulse-labelling with 4-thiouridine. Cells were labelled on 10 cm dishes at 
70% confluence with 200 uM 4-thiouridine (4sU, Sigma Aldrich) for 60 minutes as 
described30. RNA was extracted with Trizol. 4-thiouridine containing mRNA 
molecules were biotinylated with biotin-HPDP (EZ-Link Biotin-HPDP, Pierce, Cat 
#21341), and purified with the uMACS streptavidin kit (Miltenyi Biotec). RNA was 
eluted in 100 mM DTT, cDNA was synthesized, and ATF4 levels quantified and 
normalized to b-actin.  
Reagents. Serine and glycine were purchased from Sigma Aldrich. RPMI 
media lacking serine and glycine was custom prepared by Life Technologies.  
Real-time PCR. RNA was isolated using an RNeasy kit (Qiagen). cDNA 
was synthesized using the Superscript VILO Master mix and analysed by 
quantitative PCR (q-PCR) using Fast Sybr green master mix on a Step One 
Real-Time PCR system (all Life Technologies). Target gene expression was 
normalized to actin expression, and shown relative to control samples. Primer 
sequences can be found in Supplementary Table 4.  
siRNA transfection. 100,000 cells/well were reverse transfected in 800 ul 
of growth media in 12 well dishes. 2 ul DharmaFECT Duo was combined with 
%((!
100 pmol siRNA in a final volume of 200 ul according to the manufacturer’s 
instructions, which was then added to the cells. Cells were analysed after 2 days. 
Dharmacon ON-TARGET plus non-targeting siRNA (D-001810-10) and NFE2L2 
(L-003755-00-0005) pools were used.  
Soft agar assays. Soft agar assays were performed in triplicate in 6-well 
dishes. A 1 mL base layer of 0.8% agar in RPMI was plated and allowed to 
solidify, then 5,000 cells/well were plated in 0.4% agar on top. 1mL of RPMI was 
added the following day to each well, and changed as needed. NB: RPMI 
contains serine and glycine. Soft agar was stained with 0.01% crystal violet in 
4%PFA/PBS solution and imaged in a ChemiDoc system (Bio-Rad). Colonies 
were quantified with Image J. 
Statistical analysis. Data were analysed using a two-sided unpaired 
Student’s t test and the Mantel-Cox test was used for survival analyses. For all 
statistical analyses GraphPad Prism 6 software was used, and values of p < 0.05 
were considered statistically significant (*P < 0.05; **P < 0.01; ***P < 0.001). The 
mean ± standard error of the mean of at least three independent experiments 
performed in triplicates is reported. For all experiments similar variances between 
groups were observed. Normal distribution of samples was not determined. 
Western blotting. Protein lysates were prepared using RIPA lysis buffer 
and separated on 4–12% NuPAGE gels (Invitrogen), transferred onto a 
nitrocellulose membrane (Millipore) and incubated with the following antibodies: 
ACTIN (ab6276) and NRF2 (EP1808Y) mAb (both Abcam), NQO1 (HPA007308) 
and PHGDH (HPA021241) (both Sigma), PSAT1 (PA5-22124, Pierce), and ATF4 
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(11815, Cell Signaling). Alternatively, nuclear extracts were prepared as 
described31. Histone extracts were prepared with the Histone Extraction Kit 
according to the manufacturer’s instructions (Abcam, ab113476). Histone 
extracts were probed with the following antibodies: H3K4me3 (9727, Cell 
Signaling), H3K27me3 (07-449, Millipore), total H3 (4499, Cell Signaling).  
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Supplementary Materials 
 
 
Figure S2.1. DTT spontaneously reduces resazurin. Resazruin was incubated 
in Tris (pH 8.5) buffer with or without DTT and the fluorescence of resorufin 
(550/585nm Ex/Em) measured over time measured.  
 
 
 
Figure S2.2. CBR-5884 selectively inhibits the proliferation of melanoma 
lines with a high propensity for serine synthesis. Proliferation assay for 
melanoma lines treated at the indicated CBR-5884 concentration in (A) serine 
replete (+SER) or (B) serine deplete (-SER) media. Wm266-3 cells are PHGDH 
amplified. GAK cells were not included in –SER experiments because they are 
sensitive to serine withdrawal. Histograms depict mean ± standard error (n " 3). 
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Figure S2.3. Knockdown of PHGDH in a panel of melanoma lines.  
Proliferation assay for lines grown in (A) serine replete media (+SER) or (B) 
serine deplete media (-SER) with PHGDH knockdown (sh1 & sh2) or a 
nontargeting control (shGFP). GAK cells were not included in –SER experiments 
because they are sensitive to serine withdrawal. Histograms depict mean ± 
standard error (n " 3). 
 
 
 
Figure S2.4. The acid derivative of CBR-5884 is not active on cells. MDA-
MB-468 cells (PHGDH amplified) and MCF-10A cells were treated with the acid 
derivative of CBR-5884 for three days before assaying relative cell numbers. 
Despite CBR-5884 strongly inhibiting the proliferation of MDA-MB-468 cells, the 
acid derivative was unable to inhibit MDA-MB-468 proliferation.  
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Figure S2.5. Western blot confirming PHGDH knockdown in breast and 
melanoma lines. On the day of seeding for the proliferation assays in serine 
replete or deplete media, the indicated lysates were harvested and PHGDH 
knockdown was confirmed by western blotting. PHGDH knockdown: sh1 and 
sh2. Nontargeting control: shGFP. 
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Figure S3.1. Chromatograms from LCMS experiments to detect CBR-5884 
and GSH adducts. The tert-butyl derivative of CBR-5884 at 5mM (labeled 
C1635 in figure) was incubated with 5mM glutathione (1:1 molar ratio) and 
analyzed by LCMS. CBR-5884 and glutathione were incubated for (A) 0h, (B) 
0.5h, (C) 1h, and (D) 10h prior to LCMS analysis. To confirm that the species 
was indeed the predicted CBR-5884 and GSH adduct with loss of cyanide, an 
excess of (E) dithiothreitol was added which resulted in nearly complete recovery 
of a compound consistent with the free thiol by mass spectrometry. On the left, 
LC chromatograms are presented. Labeled peaks were identified via MS. C-
1635, tert-butyl derivative of CBR-5884. C-1635-GSH, glutathione adduct. C-
1635 thiol, free thiol resulting from cyanide loss.  
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Figure S3.2. Specific activity of full length PHGDH versus PHGDH3-314. The 
specific activity of full length PHGDH and truncated PHGDH3-314 was determined 
from the initial reaction rate normalized to the protein input. Initial rates were 
determined at a variety of substrate combinations as indicated.  
 
